Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 147-94-4] Cytarabine
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-13605 |
| Brand: | MCE |
| CAS: | 147-94-4 |
Overview
| MDL | MFCD00066487 |
|---|---|
| Molecular Weight | 243.22 |
| Molecular Formula | C9H13N3O5 |
| SMILES | O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N |
For research use only. We do not sell to patients.
28 Publications Citing Use of MCE
- [1]Cell. 2018 Sep 20;175(1):171-185.e25.
- [2]Cell Death Differ. 2022 Mar 28.
- [3]ACS Appl Mater Interfaces. 2022 Dec 20.
- [4]Leukemia. 2021 Mar 29.
- [5]Stem Cell Reports. 2021 Nov 9;16(11):2659-2673.
- [6]Cancer Lett. 27 October 2022, 215981.
- [7]Clin Chem. 2019 Dec;65(12):1522-1531.
- [8]J Exp Clin Cancer Res. 2022 Dec 9;41(1):340.
- [9]Cell Death Dis. 2022 Apr 20;13(4):379.
- [10]Cell Death Dis. 2021 Jan 5;12(1):20.
- [11]Cancers (Basel). 2022 Oct 19;14(20):5127.
- [12]Acta Pharmacol Sin. 2021 Jan;42(1):108-114.
- [13]Biochem Pharmacol. 2022 Feb 19;198:114948.
- [14]Mol Brain. 2020 Dec 10;13(1):166.
- [15]J Virol. 2021 Jan 6;JVI.01272-20.
- [16]J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
- [17]Mol Pharm. 2021 Mar 29.
- [18]J Biol Chem. 2022 Dec 14;102798.
- [19]Eur J Pharmacol. 2021 Dec 22;174722.
- [20]Front Genet. 05 August 2021.
- [21]Biomed Mater. 2020 Apr 28;15(3):035016.
- [22]Neurotox Res. 2021 Oct 15.
- [23]SLAS Discov. 2018 Aug;23(7):687-696.
- [24]Biol Pharm Bull. 2021 Oct 1.
- [25]Asian Pac J Cancer Prev. 2023 Jan 1;24(1):185-194.
- [26]Research Square Print. September 9th, 2022.
- [27]Research Square Preprint. 2022 Jun.
- [28]Fish Shellfish Immunol. 2019 Sep;92:889-896.
Summary
Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase . Cytarabine inhibits DNA synthesis with an IC 50 of 16 nM. Cytarabine has antiviral effects against HSV . Cytarabine shows anti-orthopoxvirus activity.
IC50 & Target
|
Microbial Metabolite
|
HSV-1
|
In Vitro
Cytarabine is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC 50 of 16 nM [1] . Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity [3] . Cytarabine is highly effective against acute leukaemias, which causes the Cytarabine teristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01801046 | University of Southern California|National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myeloid Leukemia in Remission|Childhood Acute Myelomonocytic Leukemia (M4)|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
March 6, 2013 | Phase 1 |
| NCT04845035 | University of Michigan Rogel Cancer Center|Takeda |
Acute Lymphoblastic Leukemia
|
October 2022 | Phase 2 |
| NCT00023777 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
August 2001 | Phase 2 |
| NCT02577406 | Celgene |
Leukemia, Myeloid|Isocitrate Dehydrogenase
|
December 30, 2015 | Phase 3 |
| NCT04158739 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
January 6, 2020 | Phase 1 |
| NCT02029417 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Teva Pharmaceutical Industries, Ltd. |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
July 2014 | Phase 2 |
| NCT04029688 | Hoffmann-La Roche |
Acute Myeloid Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Neuroblastoma|Solid Tumors
|
January 27, 2020 | Phase 1|Phase 2 |
| NCT02416908 | Washington University School of Medicine|Karyopharm Therapeutics Inc |
Acute Myeloid Leukemia
|
June 16, 2015 | Phase 1|Phase 2 |
| NCT04174612 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Acute Myeloid Leukemia With FLT3+ITD Mutation
|
April 24, 2020 | Phase 3 |
| NCT05146739 | National Cancer Institute (NCI)|Childrens Oncology Group (COG)|LLS PedAL LLC |
Down Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory Myelodysplastic Syndrome|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome
|
August 19, 2022 | Phase 1 |
| NCT00003407 | Rush University Medical Center|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Leukemia|Myelodysplastic Syndromes|Neutropenia
|
April 1998 | Phase 2 |
| NCT03488225 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia in Remission|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
March 28, 2018 | Phase 2 |
| NCT02342782 | City of Hope Medical Center|National Cancer Institute (NCI) |
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
|
June 8, 2020 | Phase 1 |
| NCT00973752 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Enzon Pharmaceuticals, Inc.|Genzyme, a Sanofi Company |
Acute Lymphoblastic Leukemia
|
August 2009 | Phase 2 |
| NCT02981628 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory B Lymphoblastic Lymphoma
|
June 5, 2017 | Phase 2 |
| NCT01289457 | M.D. Anderson Cancer Center |
Leukemia
|
February 2, 2011 | Phase 1|Phase 2 |
| NCT01681537 | Massachusetts General Hospital |
Acute Myelogenous Leukemia
|
September 2012 | Phase 1 |
| NCT00780143 | PharmaMar |
Relapsed+Refractory Leukemia
|
November 2007 | Phase 1|Phase 2 |
| NCT02649764 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Chronic Myelomonocytic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory High Risk Myelodysplastic Syndrome
|
May 4, 2016 | Phase 1 |
| NCT02105116 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
February 2014 | Not Applicable |
| NCT05564390 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
February 28, 2023 | Phase 2 |
| NCT01476839 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Adult Hodgkin Lymphoma
|
November 9, 2012 | Phase 1 |
| NCT01005914 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Leukemia
|
June 2009 | Phase 2 |
| NCT05319587 | Moleculin Biotech, Inc. |
Leukemia, Myeloid, Acute
|
September 29, 2022 | Phase 1|Phase 2 |
| NCT00454480 | The University of New South Wales|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
August 2006 | Phase 2|Phase 3 |
| NCT03206671 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany) |
Mature B-cell Non-Hodgkin Lymphoma
|
August 3, 2017 | Phase 3 |
| NCT03330821 | University of Southern California|National Cancer Institute (NCI) |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Therapy-Related Acute Myeloid Leukemia
|
April 18, 2018 | Phase 1|Phase 2 |
| NCT00003957 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
December 1998 | Phase 2 |
| NCT00381680 | Children´s Oncology Group|National Cancer Institute (NCI) |
B-cell Childhood Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
|
March 2007 | Phase 3 |
| NCT01567059 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Multilineage Dysplasia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Myeloid Leukemia
|
May 2012 | Phase 2 |
| NCT03760445 | Novartis Pharmaceuticals|Novartis |
Leukemia, Myeloid, Acute
|
November 15, 2019 | Phase 1|Phase 2 |
| NCT00920153 | French Innovative Leukemia Organisation |
Lymphoma
|
May 2008 | Phase 3 |
| NCT02894645 | National University Hospital, Singapore |
Acute Lymphoblastic Leukemia (ALL)
|
October 2008 | Phase 4 |
| NCT03623373 | Washington University School of Medicine|Acerta Pharma BV |
Mantle Cell Lymphoma
|
November 29, 2018 | Phase 2 |
| NCT00609739 | Masonic Cancer Center, University of Minnesota |
Leukemia
|
June 1999 | Phase 1|Phase 2 |
| NCT05554393 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
February 28, 2023 | Phase 2 |
| NCT04115631 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Liver Lymphoma|Mantle Cell Lymphoma
|
October 3, 2019 | Phase 2 |
| NCT01478074 | Altor BioScience|M.D. Anderson Cancer Center |
Acute Myeloid Leukemia
|
November 2011 | Phase 1 |
| NCT00040690 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
November 2008 | Phase 2 |
| NCT04043494 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany) |
Lymphoblastic Lymphoma, Childhood
|
August 23, 2019 | Phase 3 |
| NCT02013648 | University of Ulm |
Acute Myeloid Leukemia (AML)
|
July 2014 | Phase 3 |
| NCT04087967 | The First Affiliated Hospital of Soochow University|Second Affiliated Hospital of Soochow University|Changzhou No.2 People´s Hospital|The First People´s Hospital of Lianyungang|Jingjiang People´s Hospital|Zhangjiagang First People´s Hospital|The Second People´s Hospital of Huai´an|The Third People´s Hospital of Kunshan |
Acute Myeloid Leukemia|Induction Chemotherapy
|
April 1, 2019 | Phase 3 |
| NCT00002552 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
October 1993 | Phase 2 |
| NCT00647049 | University Hospital Freiburg|University Hospital Tuebingen |
Primary Non Hodgkin Lymphoma of the Central Nervous System
|
January 2007 | Phase 2 |
| NCT00002549 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia
|
November 1993 | Phase 3 |
| NCT02877303 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
November 1, 2016 | Phase 2 |
| NCT00528398 | City of Hope Medical Center|National Cancer Institute (NCI) |
Leukemia
|
September 1994 | Phase 2 |
| NCT05342584 | Ioannis Mantzaris|Montefiore Medical Center |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
May 25, 2022 | Phase 1 |
| NCT01831232 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Refractory Anemia With Excess Blasts|Untreated Adult Acute Myeloid Leukemia
|
May 2013 | Not Applicable |
| NCT05228249 | Fred Hutchinson Cancer Center|ADC Therapeutics |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
|
December 7, 2022 | Phase 1 |
| NCT04196010 | University of Washington |
Myeloid Neoplasm|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
May 8, 2020 | Phase 1 |
| NCT02717884 | Michael Luebbert|University Hospital Freiburg |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
May 2015 | Phase 1|Phase 2 |
| NCT00003268 | Sidney Kimmel Cancer Center at Thomas Jefferson University|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Leukemia
|
January 1998 | Phase 1 |
| NCT00002744 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
May 1996 | Phase 3 |
| NCT03258931 | Arog Pharmaceuticals, Inc. |
Newly Diagnosed FLT3 Mutated AML
|
August 15, 2018 | Phase 3 |
| NCT01253070 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia With FLT3+ITD Mutation|Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Acute Promyelocytic Leukemia With PML-RARA|FLT3 Gene Mutation|Therapy-Related Acute Myeloid Leukemia
|
April 1, 2011 | Phase 2 |
| NCT01861002 | Therapeutic Advances in Childhood Leukemia Consortium|Gateway for Cancer Research |
Lymphoblastic Leukemia, Acute, Childhood|Myelogenous Leukemia, Acute, Childhood
|
May 22, 2013 | Phase 1 |
| NCT00390793 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|t(9;22)
|
September 28, 2006 | Phase 2 |
| NCT00002868 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
January 1996 | Phase 3 |
| NCT00002812 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
September 1996 | Phase 3 |
| NCT00002494 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
May 1992 | Phase 2 |
| NCT00691015 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
May 2008 | Phase 2 |
| NCT00015834 | National Cancer Institute (NCI) |
Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Relapsing Chronic Myelogenous Leukemia
|
May 2001 | Phase 1|Phase 2 |
| NCT02229266 | Technische Universität Dresden|German Research Foundation |
Acute Myeloid Leukemia
|
September 2015 | Phase 2 |
| NCT00078949 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lymphoma
|
August 7, 2003 | Phase 3 |
| NCT04526795 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent T-Cell Prolymphocytic Leukemia|Refractory Acute Biphenotypic Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory T-Cell Prolymphocytic Leukemia
|
April 9, 2021 | Phase 1 |
| NCT02339740 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Promyelocytic Leukemia With PML-RARA
|
June 29, 2015 | Phase 3 |
| NCT02791919 | National Cancer Institute (NCI) |
CNS 2a|CNS 2b|CNS 2c|CNS1|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia
|
May 25, 2017 | Phase 1 |
| NCT02652871 | M.D. Anderson Cancer Center|Eli Lilly and Company|High Impact Clinical Research Support Program |
Leukemia
|
May 9, 2016 | Phase 1 |
| NCT00004263 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
December 1999 | Phase 1 |
| NCT00873093 | National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
March 2009 | Phase 2 |
| NCT00002547 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
August 1987 | Phase 2 |
| NCT00077116 | European Organisation for Research and Treatment of Cancer - EORTC |
Leukemia|Myelodysplastic Syndromes
|
November 2003 | Phase 2 |
| NCT02582359 | Massachusetts General Hospital|Millennium Pharmaceuticals, Inc. |
Acute Myeloid Leukemia
|
January 2016 | Phase 1 |
| NCT03007147 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia
|
July 28, 2017 | Phase 3 |
| NCT00853008 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
January 2003 | Phase 4 |
| NCT01399372 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Chemotherapeutic Agent Toxicity|Cognitive+Functional Effects|Lymphoma|Neurotoxicity|Radiation Toxicity
|
September 2011 | Phase 2 |
| NCT02576301 | Mateon Therapeutics |
Acute Myelogenous Leukemia|Myelodysplastic Syndromes
|
October 2015 | Phase 1|Phase 2 |
| NCT04530565 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
October 14, 2020 | Phase 3 |
| NCT01921387 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma
|
October 9, 2013 | Phase 1|Phase 2 |
| NCT00002761 | Columbia University |
Leukemia
|
February 1996 | Phase 1|Phase 2 |
| NCT00004114 | Jonsson Comprehensive Cancer Center |
Leukemia|Lymphoma|Myelodysplastic Syndromes
|
Phase 1 | |
| NCT01661881 | Dana-Farber Cancer Institute|Massachusetts General Hospital |
Mantle Cell Lymphoma
|
August 16, 2012 | Phase 2 |
| NCT02323607 | Bhavana Bhatnagar|CTI BioPharma|Ohio State University Comprehensive Cancer Center |
Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
January 12, 2016 | Phase 1 |
| NCT00199056 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
October 1999 | Phase 4 |
| NCT03135028 | Gilead Sciences |
Hematologic Malignancy|Acute Myeloid Leukemia
|
May 19, 2017 | Phase 1 |
| NCT02633137 | Memorial Sloan Kettering Cancer Center|Celgene Corporation |
Mantle Cell Lymphoma|Untreated
|
December 14, 2015 | Phase 2 |
| NCT04275518 | Ascentage Pharma Group Inc.|Suzhou Yasheng Pharmaceutical Co., Ltd. |
Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)
|
July 6, 2020 | Phase 1 |
| NCT00831766 | H. Lee Moffitt Cancer Center and Research Institute|Celgene |
Myelodysplastic Syndrome|Acute Myeloid Leukemia
|
June 25, 2009 | Phase 1|Phase 2 |
| NCT00005585 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2000 | Phase 3 |
| NCT00003436 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
July 1998 | Phase 3 |
| NCT04797767 | University of Washington|AbbVie |
Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Mixed Phenotype Acute Leukemia|Myeloid Neoplasm|Relapsed Acute Biphenotypic Leukemia|Relapsed Acute Myeloid Leukemia|Relapsed Mixed Phenotype Acute Leukemia|Relapsed Myeloid Neoplasm|Refractory Acute Biphenotypic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory Myeloid Neoplasm
|
February 4, 2022 | Phase 1 |
| NCT01481272 | Polish Lymphoma Research Group |
Diffuse Large B Cell Lymphoma
|
November 2011 | Phase 2 |
| NCT03412409 | Peking University People´s Hospital |
Acute Leukemia|Myelodysplastic Syndromes
|
February 1, 2018 | Phase 2 |
| NCT00002571 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 1994 | Phase 2 |
| NCT03013998 | Beat AML, LLC |
Previously Untreated Acute Myeloid Leukemia
|
November 2016 | Phase 1|Phase 2 |
| NCT00023920 | National Cancer Institute (NCI) |
Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive
|
July 2001 | Phase 2 |
| NCT00002691 | Memorial Sloan Kettering Cancer Center |
Lymphoma
|
August 1995 | Phase 2 |
| NCT03661515 | PETHEMA Foundation |
Acute Myeloid Leukemia
|
July 17, 2018 | Phase 1 |
| NCT02728050 | University of Washington|National Cancer Institute (NCI)|Bayer |
Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome|Myeloproliferative Neoplasm
|
December 1, 2016 | Phase 1|Phase 2 |
| NCT04107727 | PETHEMA Foundation|Dynamic Science S.L.|Daiichi Sankyo, Inc. |
Acute Myeloid Leukemia
|
September 5, 2019 | Phase 2 |
| NCT00002674 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
October 1994 | Phase 2 |
| NCT02502968 | Dr. Petra Tschanter|BioLineRx, Ltd.|Martin-Luther-Universität Halle-Wittenberg |
Acute Myeloid Leukemia
|
September 2015 | Phase 2 |
| NCT02413021 | Isfahan University of Medical Sciences |
Acute Myeloid Leukemia|Acute Lymphoid Leukemia
|
May 2016 | Phase 1 |
| NCT00199082 | Nicola Goekbuget|Goethe University |
Burkitt´s Lymphoma|Burkitt´s Leukemia|Mediastinal Neoplasms|Lymphoblastic Lymphoma|Large Cell Anaplastic Lymphoma
|
July 2002 | Phase 4 |
| NCT03518112 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Philadelphia Chromosome Negative|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia
|
April 18, 2018 | Phase 2 |
| NCT03441048 | Medical College of Wisconsin |
Acute Myeloid Leukemia
|
May 22, 2018 | Phase 1 |
| NCT00049517 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 2002 | Phase 3 |
| NCT00270881 | Keio University |
Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome
|
January 2006 | Phase 1|Phase 2 |
| NCT00410423 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Millennium Pharmaceuticals, Inc.|Thomas Jefferson University |
Relapsed Acute Leukemia|Refractory Acute Leukemia
|
January 2006 | Phase 1|Phase 2 |
| NCT02412475 | Michael Burke|Children´s Hospitals and Clinics of Minnesota|Medical College of Wisconsin |
Leukemia, Acute Myeloid
|
February 21, 2015 | Phase 1 |
| NCT00968253 | M.D. Anderson Cancer Center|Novartis |
Leukemia|Acute Lymphocytic Leukemia
|
November 2009 | Phase 1|Phase 2 |
| NCT00098839 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent Childhood Acute Lymphoblastic Leukemia
|
February 2005 | Phase 1|Phase 2 |
| NCT05466318 | Sichuan University |
Lymphoma, Large B-Cell, Diffuse|Lymphoma, T-Cell
|
July 1, 2022 | Phase 3 |
| NCT00074165 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Drug+Agent Toxicity by Tissue+Organ|Lymphoma|Thrombocytopenia
|
January 2003 | Phase 2 |
| NCT00199004 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
April 2004 | Phase 4 |
| NCT02101853 | National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia
|
December 8, 2014 | Phase 3 |
| NCT01349972 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
April 2011 | Phase 2 |
| NCT00006695 | University of Nebraska |
Lymphoma
|
April 2000 | Phase 2 |
| NCT00049569 | National Cancer Institute (NCI) |
L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Non-T, Non-B Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
January 2003 | Not Applicable |
| NCT01444742 | M.D. Anderson Cancer Center |
Leukemia|Myeloproliferative Diseases
|
November 16, 2011 | Phase 2 |
| NCT00343369 | Universitätsklinikum Hamburg-Eppendorf|National Cancer Institute (NCI) |
Leukemia
|
January 2003 | Not Applicable |
| NCT02310321 | Astellas Pharma Inc |
Acute Myeloid Leukemia|FLT3-mutated Acute Myeloid Leukemia
|
February 26, 2015 | Phase 1|Phase 2 |
| NCT03571321 | University of Chicago|Incyte Corporation |
Acute Lymphoblastic Leukemia|ALL, Childhood|ALL
|
May 28, 2019 | Phase 1 |
| NCT00715637 | Antisoma Research |
Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
|
June 2007 | Phase 3 |
| NCT00107354 | Fred Hutchinson Cancer Center |
Leukemia|Myelodysplastic Syndromes
|
December 1998 | Phase 1 |
| NCT00002531 | Johann Wolfgang Goethe University Hospital|National Cancer Institute (NCI) |
Leukemia
|
January 1993 | Phase 2 |
| NCT02756572 | University of Washington|National Cancer Institute (NCI) |
Blasts 10 Percent or More of Bone Marrow Nucleated Cells|Chronic Myelomonocytic Leukemia-2|High Grade Malignant Neoplasm|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts-2|Myeloid Neoplasm|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
September 22, 2016 | Phase 2 |
| NCT00992134 | St. Bortolo Hospital |
Lymphoma, Mantle-Cell
|
June 2009 | Phase 2 |
| NCT02484391 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Granulocytic Sarcoma|Recurrent Adult Acute Myeloid Leukemia
|
September 2015 | Phase 2 |
| NCT05601466 | Institute of Hematology & Blood Diseases Hospital|Hangzhou Qihan Biotech Co.,Ltd. |
AML, Adult
|
October 28, 2022 | Phase 1 |
| NCT00002609 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
August 1994 | Phase 2 |
| NCT01463046 | University of California, San Francisco|Novartis |
Acute Myeloid Leukemia|Advanced Myelodysplastic Syndrome
|
January 2012 | Phase 1 |
| NCT03959085 | Children´s Oncology Group|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Central Nervous System Leukemia|Mixed Phenotype Acute Leukemia|Testicular Leukemia
|
October 28, 2019 | Phase 3 |
| NCT00634244 | National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia
|
October 2008 | Phase 2 |
| NCT00005985 | Masonic Cancer Center, University of Minnesota |
Lymphoma
|
August 2000 | Phase 2 |
| NCT02044796 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Acute Biphenotypic Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
January 23, 2014 | Phase 1|Phase 2 |
| NCT01141712 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program |
Lymphoma|HIV
|
April 2010 | Phase 2 |
| NCT00439556 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CD20 Positive|Hematopoietic and Lymphoid Cell Neoplasm|Lymphocytic Neoplasm|Lymphoma
|
February 13, 2007 | Phase 2 |
| NCT00440726 | Therapeutic Advances in Childhood Leukemia Consortium |
Acute Lymphoblastic Leukemia
|
August 4, 2006 | Phase 1|Phase 2 |
| NCT00357305 | National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes
|
May 2006 | Phase 1 |
| NCT00002534 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
May 1993 | Phase 3 |
| NCT00070551 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia
|
September 2003 | Phase 1 |
| NCT03837873 | Institute of Hematology & Blood Diseases Hospital |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Transformed Lymphoma
|
January 21, 2019 | Phase 2 |
| NCT00080886 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma
|
May 2002 | Phase 2 |
| NCT03069352 | AbbVie |
Acute Myeloid Leukemia (AML)
|
May 23, 2017 | Phase 3 |
| NCT01156883 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia
|
April 2010 | Not Applicable |
| NCT03583424 | Ohio State University Comprehensive Cancer Center |
Hematopoietic Cell Transplantation Recipient|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Indolent Non-Hodgkin Lymphoma
|
September 10, 2018 | Phase 1|Phase 2 |
| NCT00016302 | National Cancer Institute (NCI) |
T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia
|
April 2001 | Not Applicable |
| NCT03983824 | National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
October 4, 2019 | Phase 1 |
| NCT03589326 | Takeda |
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph&addition;ALL)
|
August 10, 2018 | Phase 3 |
| NCT00002499 | Grupo Argentino de Tratamiento de la Leucemia Aguda|National Cancer Institute (NCI) |
Leukemia
|
January 1990 | Phase 2|Phase 3 |
| NCT02985372 | Chunyan Ji|Binzhou Medical University|Shengli Oilfield Central Hospital|Heze Municipal Hospital|Jinan Military Genaral Hospital|Jinan Central Hospital|Jining Medical University|Linyi People´s Hospital|Qingdao University|Rizhao People´s Hospital|Qianfoshan Hospital|Qilu Hospital of Shandong University (Qingdao)|Taian City Central Hospital|Taishan Medical University Affiliated Hospital|Weihai Municipal Hospital|Weifang Medical University|Zibo First Hospital|Central Hospital of Zibo|Shandong University |
Acute Myeloid Leukemia, Adult
|
December 2016 | Phase 3 |
| NCT03519984 | University of Southern California|National Cancer Institute (NCI)|Vasgene Therapeutics, Inc|Whittier Foundation |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|Myelodysplastic+Myeloproliferative Neoplasm|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|T Acute Lymphoblastic Leukemia
|
May 9, 2018 | Phase 1 |
| NCT00002590 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
July 1994 | Phase 2 |
| NCT00003239 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
March 1998 | Phase 2 |
| NCT03507842 | Asan Medical Center |
Acute Myeloid Leukemia
|
March 1, 2018 | Phase 3 |
| NCT03226418 | University of Nebraska|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia
|
July 7, 2017 | Phase 2 |
| NCT01056523 | Jewish General Hospital|The Leukemia and Lymphoma Society |
Acute Myeloid Leukemia
|
January 2010 | Phase 1|Phase 2 |
| NCT02680951 | Emory University |
Acute Myeloid Leukemia
|
December 2015 | Phase 1 |
| NCT00209222 | European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association |
Lymphoma, Mantle-Cell
|
July 2004 | Phase 3 |
| NCT00006363 | National Cancer Institute (NCI) |
Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Erythroid Leukemia (M6)|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Childhood Acute Basophilic Leukemia|Childhood Acute Eosinophilic Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
November 2000 | Phase 3 |
| NCT00354276 | Vion Pharmaceuticals|National Cancer Institute (NCI) |
Leukemia
|
May 2006 | Phase 2 |
| NCT00074737 | Eleos, Inc. |
Acute Myelogenous Leukemia
|
April 2004 | Phase 2 |
| NCT05521087 | Janssen Research & Development, LLC |
Acute Leukemias|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Acute Leukemia of Ambiguous Lineage
|
December 22, 2022 | Phase 1 |
| NCT03813147 | National Cancer Institute (NCI)|Children´s Oncology Group |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome
|
May 1, 2019 | Phase 1 |
| NCT02115295 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts 10 Percent or More of Bone Marrow Nucleated Cells|Blasts 10 Percent or More of Peripheral Blood White Cells|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
May 19, 2014 | Phase 2 |
| NCT04752163 | M.D. Anderson Cancer Center |
Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome
|
March 25, 2021 | Phase 1|Phase 2 |
| NCT00028847 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Leukemia
|
April 2001 | Phase 1|Phase 2 |
| NCT00046930 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Eli Lilly and Company|Kanisa Pharmaceuticals |
Leukemia|Myelodysplastic Syndromes
|
July 2002 | Phase 3 |
| NCT00038610 | M.D. Anderson Cancer Center|Novartis Pharmaceuticals |
Leukemia
|
March 2001 | Phase 2 |
| NCT04254640 | Sun Yat-sen University |
Acute Myeloid Leukemia|Elderly Patients|Newly Diagnosed
|
March 1, 2021 | Phase 2 |
| NCT05320380 | LLS PedAL Initiative, LLC|Children´s Oncology Group|ImmunoGen, Inc.|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory T Acute Lymphoblastic Leukemia
|
December 20, 2022 | Phase 1|Phase 2 |
| NCT02834390 | Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc. |
Acute Myeloid Leukemia
|
August 12, 2016 | Phase 1 |
| NCT02212561 | St. Jude Children´s Research Hospital|Karyopharm Therapeutics Inc |
Acute Myeloid Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)|Myelodysplastic Syndrome (MDS)|Mixed Phenotype Acute Leukemia (MPAL)
|
August 2014 | Phase 1 |
| NCT00003694 | National Cancer Institute (NCI) |
Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia
|
March 1999 | Phase 2 |
| NCT00039117 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
April 2002 | Phase 1 |
| NCT00907517 | Merck Sharp & Dohme LLC |
Myelogenous Leukemia, Acute|Leukemia, Lymphocytic, Acute|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive|Myelogenous Leukemia, Chronic, Aggressive Phase
|
July 29, 2009 | Phase 1 |
| NCT00469859 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 2007 | Phase 1|Phase 2 |
| NCT00002701 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto|National Cancer Institute (NCI) |
Leukemia
|
October 1995 | Phase 3 |
| NCT01184898 | Sidney Kimmel Cancer Center at Thomas Jefferson University|University of Pennsylvania|Thomas Jefferson University |
AML
|
July 2010 | Not Applicable |
| NCT01641250 | Hoffmann-La Roche |
Myelogenous Leukemia, Acute
|
August 2012 | Phase 1 |
| NCT01794702 | M.D. Anderson Cancer Center |
Leukemia
|
February 20, 2013 | Phase 1|Phase 2 |
| NCT00002865 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Leukemia
|
April 1995 | Phase 2 |
| NCT01412879 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2011 | Phase 2 |
| NCT03381118 | St. Petersburg State Pavlov Medical University |
Acute Myeloid Leukemia
|
June 30, 2017 | Phase 2 |
| NCT02144675 | Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
January 2009 | Phase 2 |
| NCT02070458 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
October 8, 2014 | Phase 1 |
| NCT00209833 | Hannover Medical School|University of Ulm|Johann Wolfgang Goethe University Hospital|University Hospital Freiburg|University Hospital Augsburg|Humboldt-Universität zu Berlin|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Ghent|Medizinische Universitätsklinik Tübingen|Klinikum Hanover-Siloah Hospital|Ev. Krankenhaus Essen-Werden|Klinikum Wuppertal GmbH |
De Novo Akute Myeloid Leukemia (AML)|Secondary Acute Myeloid Leukemia (AML)|Refractory Anemia With Excess of Blasts in Transformation
|
January 1999 | Phase 2|Phase 3 |
| NCT01085617 | University College, London |
Leukemia|Mucositis|Oral Complications
|
December 2010 | Phase 3 |
| NCT02741388 | The Lymphoma Academic Research Organisation|Karyopharm Therapeutics Inc |
B-cell Lymphoma
|
October 2016 | Phase 1 |
| NCT01497002 | University of Leipzig |
Acute Myeloid Leukaemia
|
April 2005 | Phase 3 |
| NCT00666588 | National Cancer Institute (NCI) |
Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Childhood Acute Basophilic Leukemia|Childhood Acute Eosinophilic Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myelomonocytic Leukemia (M4)|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
April 2008 | Phase 2 |
| NCT00317408 | European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma|National Cancer Institute (NCI) |
Lymphoma
|
April 2004 | Not Applicable |
| NCT00069966 | Theradex|National Cancer Institute (NCI) |
Lymphoma
|
April 2003 | Phase 2 |
| NCT00020943 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
June 2001 | Phase 2 |
| NCT03092674 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts-2
|
December 22, 2017 | Phase 2|Phase 3 |
| NCT00795756 | Northern Italy Leukemia Group |
Acute Lymphoblastic Leukemia
|
January 2008 | Phase 2|Phase 3 |
| NCT02328950 | Fujian Medical University |
Myelodysplastic Syndromes|Leukemia, Myeloid, Acute|Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
December 2014 | |
| NCT02135874 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Undifferentiated Leukemia|Mixed Phenotype Acute Leukemia|Mixed Phenotype Acute Leukemia, B+Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T+Myeloid, Not Otherwise Specified|Recurrent Mixed Phenotype Acute Leukemia
|
October 27, 2014 | Phase 2 |
| NCT00002638 | University of Nebraska|National Cancer Institute (NCI) |
Leukemia
|
March 1995 | Phase 2 |
| NCT02287233 | AbbVie|Genentech, Inc. |
Acute Myelogenous Leukemia|AML
|
December 31, 2014 | Phase 1|Phase 2 |
| NCT04190550 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
|
July 29, 2020 | Phase 1 |
| NCT00333840 | Novartis Pharmaceuticals|Novartis |
Chronic Myelogenous Leukemia
|
June 2000 | Phase 3 |
| NCT00005863 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
August 1998 | Phase 3 |
| NCT03147612 | M.D. Anderson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia With BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia
|
February 8, 2018 | Phase 2 |
| NCT01225874 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 1999 | Not Applicable |
| NCT00098423 | National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes
|
November 2004 | Phase 1 |
| NCT02575963 | Actinium Pharmaceuticals |
AML
|
October 2012 | Phase 1|Phase 2 |
| NCT00940524 | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb |
Leukemia|Acute Lymphoblastic Leukemia
|
July 2009 | Phase 1 |
| NCT01191801 | Sunesis Pharmaceuticals |
Acute Myeloid Leukemia
|
December 17, 2010 | Phase 3 |
| NCT00006367 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders
|
May 2000 | Phase 2 |
| NCT00002945 | Roswell Park Cancer Institute |
Leukemia
|
December 1996 | Phase 3 |
| NCT01190930 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Lymphoblastic Lymphoma|Ann Arbor Stage I B Lymphoblastic Lymphoma|Ann Arbor Stage II B Lymphoblastic Lymphoma|Childhood B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Lymphoblastic Lymphoma|Down Syndrome|Hypodiploid B Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive
|
August 9, 2010 | Phase 3 |
| NCT00840684 | Institut Paoli-Calmettes|National Cancer Institute (NCI) |
Leukemia
|
January 2009 | Phase 1|Phase 2 |
| NCT03504410 | Cornerstone Pharmaceuticals |
Relapsed+Refractory Acute Myeloid Leukemia
|
November 12, 2018 | Phase 3 |
| NCT00187122 | St. Jude Children´s Research Hospital |
Lymphoblastic Lymphoma
|
March 1993 | Not Applicable |
| NCT01892371 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
FLT3 Gene Mutation Negative|FLT3 Internal Tandem Duplication Positive|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome
|
November 12, 2013 | Phase 1|Phase 2 |
| NCT02573363 | University of Chicago|National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
October 7, 2015 | Phase 1 |
| NCT03634228 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
December 17, 2018 | Phase 1|Phase 2 |
| NCT00004903 | Robert H. Lurie Cancer Center|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
October 1999 | Phase 2 |
| NCT02228772 | Massachusetts General Hospital|Millennium Pharmaceuticals, Inc. |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia
|
December 2014 | Phase 1 |
| NCT01265199 | Ascenta Therapeutics|The Leukemia and Lymphoma Society |
Acute Myelogenous Leukemia (AML)
|
February 2011 | Phase 1 |
| NCT00275015 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
January 1998 | Phase 2 |
| NCT05365035 | M.D. Anderson Cancer Center |
Myelodysplastic Syndromes|Myeloproliferative Chronic Myelomonocytic Leukemia
|
September 23, 2022 | Phase 2 |
| NCT04047641 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Blasts 20 Percent or More of Bone Marrow Nucleated Cells|High Risk Myelodysplastic Syndrome|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory High Risk Myelodysplastic Syndrome
|
October 22, 2019 | Phase 1|Phase 2 |
| NCT04920500 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. |
Acute Myeloid Leukemia
|
September 4, 2020 | Not Applicable |
| NCT00503880 | University of Nebraska|National Cancer Institute (NCI) |
Myelodysplastic Syndromes
|
May 2007 | Phase 1|Phase 2 |
| NCT00487448 | PETHEMA Foundation |
Myelodysplastic Syndrome|Acute Myeloblastic Leukemia
|
July 1998 | Phase 4 |
| NCT05199051 | Centre Antoine Lacassagne|Acute Leukemia French Association |
AML
|
October 30, 2022 | Phase 2 |
| NCT00079482 | Cephalon|Teva Branded Pharmaceutical Products R&D, Inc. |
Acute Myeloid Leukemia
|
October 2003 | Phase 2 |
| NCT03553238 | Nanfang Hospital of Southern Medical University |
Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic
|
February 14, 2016 | Phase 2|Phase 3 |
| NCT01564784 | Pfizer|UCB Pharma |
Acute Lymphoblastic Leukemia
|
August 2, 2012 | Phase 3 |
| NCT00574080 | University of Arkansas |
Multiple Myeloma
|
July 2006 | Phase 3 |
| NCT00544999 | Institut de Recherche Clinique sur les Cancers et le Sang|National Cancer Institute (NCI) |
Leukemia
|
September 2007 | Phase 1 |
| NCT00096148 | National Cancer Institute (NCI) |
Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Childhood Acute Basophilic Leukemia|Childhood Acute Eosinophilic Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myelomonocytic Leukemia (M4)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
October 2004 | Phase 2 |
| NCT00136435 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Queen Elizabeth II Health Sciences Centre |
Acute Lymphoblastic Leukemia
|
June 2002 | Phase 2 |
| NCT01527149 | Roswell Park Cancer Institute|National Comprehensive Cancer Network |
Stage I Mantle Cell Lymphoma|Stage II Contiguous Mantle Cell Lymphoma|Stage II Non-Contiguous Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma
|
December 6, 2011 | Phase 2 |
| NCT00003827 | ALZA|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
January 1999 | Phase 2 |
| NCT00620321 | Eli Lilly and Company |
Acute Myeloid Leukemia
|
March 2008 | Phase 2 |
| NCT00219739 | Poitiers University Hospital|Ministry of Health, France|Novartis|Roche Pharma AG |
Chronic Myeloid Leukemia
|
September 2003 | Phase 3 |
| NCT03569995 | Won Seog Kim|Celltrion|Samsung Medical Center |
Primary CNS Lymphoma
|
November 30, 2018 | Phase 2 |
| NCT00004192 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma|Neutropenia
|
May 2000 | Phase 2 |
| NCT00439296 | Therapeutic Advances in Childhood Leukemia Consortium|Abbott |
Recurrent Pediatric ALL|Relapsed Pediatric ALL|Acute Lymphoblastic Leukemia|Refractory Pediatric ALL
|
May 22, 2006 | Phase 1|Phase 2 |
| NCT00001048 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Upjohn |
HIV Infections|Leukoencephalopathy, Progressive Multifocal
|
Phase 2 | |
| NCT01635296 | Hoffmann-La Roche |
Myelogenous Leukemia, Acute
|
July 2012 | Phase 1 |
| NCT01154439 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia
|
October 2010 | Phase 1 |
| NCT00742625 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Untreated Adult Acute Myeloid Leukemia
|
September 2008 | Phase 1|Phase 2 |
| NCT00002658 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia|Neutropenia
|
January 1994 | Phase 3 |
| NCT00052299 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia
|
September 2002 | Phase 3 |
| NCT03303339 | Cardiff Oncology |
Acute Myeloid Leukemia
|
November 17, 2017 | Phase 1|Phase 2 |
| NCT00112554 | Vion Pharmaceuticals|National Cancer Institute (NCI) |
Leukemia
|
March 2005 | Phase 3 |
| NCT02930109 | Prescient Therapeutics, Ltd. |
Acute Leukemia
|
September 2016 | Phase 1|Phase 2 |
| NCT01237808 | University of Ulm|German Federal Ministry of Education and Research |
Acute Myeloid Leukemia (AML)
|
March 2011 | Phase 3 |
| NCT02835729 | NewLink Genetics Corporation|Lumos Pharma |
Acute Myeloid Leukemia
|
July 2016 | Phase 1 |
| NCT04848974 | M.D. Anderson Cancer Center |
Secondary Acute Myeloid Leukemia
|
June 11, 2021 | Phase 1|Phase 2 |
| NCT03384654 | Janssen Research & Development, LLC |
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
May 14, 2018 | Phase 2 |
| NCT02329080 | International Extranodal Lymphoma Study Group (IELSG) |
Diffuse Large B-cell Lymphoma
|
December 2014 | Phase 2 |
| NCT00025402 | III. Medizinische Klinik Mannheim|National Cancer Institute (NCI) |
Leukemia
|
July 1997 | Phase 3 |
| NCT00096122 | National Cancer Institute (NCI) |
Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Myeloid Leukemia
|
September 2004 | Phase 1|Phase 2 |
| NCT05100303 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
December 2021 | Phase 1|Phase 2 |
| NCT03381781 | Li Junmin|Ruijin Hospital |
Acute Myeloid Leukemia|P53 Mutation
|
March 2018 | Phase 2 |
| NCT00004217 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
February 2000 | Phase 2 |
| NCT03286634 | National Hospital Organization Nagoya Medical Center |
Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer
|
April 18, 2017 | Phase 2 |
| NCT02504359 | OHSU Knight Cancer Institute|Oregon Health and Science University |
Plasma Cell Leukemia|Recurrent Plasma Cell Myeloma
|
July 20, 2015 | Phase 1 |
| NCT03459859 | Justin Watts, MD|Takeda|University of Miami |
Acute Myelogenous Leukemia|AML|Advanced Myelodysplastic Syndromes|MDS
|
May 21, 2018 | Phase 1 |
| NCT00074191 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Lymphoma
|
January 2000 | Phase 2 |
| NCT00096135 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
November 2004 | Not Applicable |
| NCT01180322 | University of Ulm |
Acute Myeloid Leukemia (AML)
|
November 2010 | Phase 2 |
| NCT00720447 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma
|
November 2008 | Phase 2 |
| NCT03735446 | Dana-Farber Cancer Institute|Eli Lilly and Company |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
January 18, 2019 | Phase 1 |
| NCT00523939 | Duke University|Enzon Pharmaceuticals, Inc. |
Neoplastic Meningitis|Lymphoma, B Cell
|
June 2006 | Phase 2 |
| NCT00002502 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes
|
July 1992 | Phase 2 |
| NCT00005601 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
October 2000 | Phase 2 |
| NCT02472626 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Untreated Adult Acute Myeloid Leukemia
|
December 2015 | Phase 1|Phase 2 |
| NCT00005998 | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) |
Lymphoma
|
January 2000 | Phase 2 |
| NCT00512252 | Washington University School of Medicine |
Leukemia, Myeloid, Acute
|
July 2007 | Phase 1|Phase 2 |
| NCT03181815 | Sun Yat-sen University |
Acute Myeloid Leukemia|Relapse Leukemia
|
January 1, 2016 | Phase 2 |
| NCT00199147 | Johann Wolfgang Goethe University Hospital |
Acute Myeloid Leukemia
|
January 2000 | Phase 4 |
| NCT03214562 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
High Risk Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
September 26, 2017 | Phase 1|Phase 2 |
| NCT01004497 | The Catholic University of Korea |
Acute Lymphoblastic Leukemia
|
March 2010 | Phase 2 |
| NCT02518750 | St. Jude Children´s Research Hospital|Novartis Pharmaceuticals|Spectrum Pharmaceuticals, Inc |
Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkin´s|Leukemia, T-Cell|Leukemia, B-Cell
|
November 23, 2016 | Phase 2 |
| NCT00345865 | Masonic Cancer Center, University of Minnesota |
Lymphoma
|
August 24, 2005 | Phase 2 |
| NCT00429416 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Hematologic Malignancies
|
March 2004 | Phase 1|Phase 2 |
| NCT00015873 | Dutch Childhood Oncology Group |
Leukemia
|
May 1999 | Phase 3 |
| NCT00005793 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|SmithKline Beecham |
Leukemia
|
July 1999 | Phase 1|Phase 2 |
| NCT00281879 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms|Unusual Cancers of Childhood
|
February 2006 | Phase 2 |
| NCT02520011 | Sumitomo Pharma Oncology, Inc. |
Acute Myeloid Leukemia
|
March 14, 2016 | Phase 2 |
| NCT00334074 | Baylor Research Institute |
Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia
|
August 2005 | Phase 2 |
| NCT02029950 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia-2|High Risk Myelodysplastic Syndrome|Myeloproliferative Neoplasm
|
December 16, 2013 | Phase 1 |
| NCT00840177 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
August 2009 | Phase 2 |
| NCT01999413 | French Innovative Leukemia Organisation|Fresenius Kabi |
Acute Myeloid Leukemia (AML)
|
November 2013 | Phase 2 |
| NCT02400281 | Arog Pharmaceuticals, Inc. |
Acute Myeloid Leukemia
|
September 2015 | Phase 1|Phase 2 |
| NCT02632708 | Institut de Recherches Internationales Servier|Celgene Corporation|Servier |
Newly Diagnosed Acute Myeloid Leukemia (AML)|Untreated AML|AML Arising From Myelodysplastic Syndrome (MDS)|AML Arising From Antecedent Hematologic Disorder (AHD)|AML Arising After Exposure to Genotoxic Injury
|
December 31, 2015 | Phase 1 |
| NCT02719574 | Forma Therapeutics, Inc. |
Acute Myeloid Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome
|
April 2016 | Phase 1|Phase 2 |
| NCT01773408 | Hoffmann-La Roche |
Myelogenous Leukemia, Acute
|
February 2013 | Phase 1 |
| NCT02983097 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH|Celgene|Amgen |
Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma Grade III (FL III�)|Mantle Cell Lymphoma (MCL), Blastoid Variant|Burkitt Lymphoma (BL)|Aggressive Marginal Zone Lymphoma (MZL)
|
November 2010 | Phase 1|Phase 2 |
| NCT00302003 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Favorable Prognosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma
|
February 2006 | Phase 3 |
| NCT00788892 | Jazz Pharmaceuticals |
Acute Myeloid Leukemia
|
October 2008 | Phase 2 |
| NCT04069208 | Peking Union Medical College Hospital |
Acute Myeloid Leukemia
|
September 3, 2019 | Phase 2 |
| NCT02319135 | PETHEMA Foundation|Dynamic Solutions |
Acute Myeloid Leukemia
|
October 2014 | Phase 3 |
| NCT00004862 | National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 1 |
| NCT00452374 | M.D. Anderson Cancer Center|Sanofi |
Leukemia
|
November 2004 | Phase 1|Phase 2 |
| NCT05292664 | Andrew E. Place|AbbVie|Servier|Children´s Cancer Research Fund|University of Colorado, Denver|Boston Children´s Hospital|Dana-Farber Cancer Institute |
Myelodysplastic Syndromes, de Novo|Myelodysplastic Syndromes, Secondary|Myelodysplastic Syndromes, Previously Treated|Treatment-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome|Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia With Failed Remission|Lymphoblastic Lymphoma, in Relapse|Lymphoblastic Lymphoma, Refractory|Acute Leukemia of Ambiguous Lineage in Relapse|Acute Leukemia of Ambiguous Lineage Not Having Achieved Remission
|
October 2022 | Phase 1 |
| NCT00180115 | Technische Universität Dresden |
Leukemia, Nonlymphoblastic, Acute
|
February 1996 | Phase 4 |
| NCT02326584 | Seagen Inc. |
Acute Myeloid Leukemia|Acute Myelogenous Leukemia
|
December 2014 | Phase 1 |
| NCT03709758 | Dana-Farber Cancer Institute|AbbVie|Genentech, Inc. |
Acute Myeloid Leukemia
|
October 17, 2018 | Phase 1 |
| NCT00591630 | M.D. Anderson Cancer Center |
Diffuse Large Cell Lymphoma|Lymphoma
|
November 14, 2007 | Phase 2 |
| NCT02658487 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia With Multilineage Dysplasia|Myeloid Sarcoma|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome
|
March 2016 | Phase 2 |
| NCT00004056 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 1 |
| NCT03207334 | University of Florida|Novartis Pharmaceuticals |
Acute Myeloid Leukemia
|
November 2018 | Phase 2 |
| NCT02481310 | Northwestern University|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. |
Adult Burkitt Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|MYC Gene Mutation|Plasmablastic Lymphoma
|
October 28, 2015 | Phase 1|Phase 2 |
| NCT00792948 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Adult L1 Acute Lymphoblastic Leukemia|Adult L2 Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia
|
September 1, 2009 | Phase 2 |
| NCT02306291 | GlycoMimetics Incorporated |
Leukemia, Myeloid, Acute
|
March 2015 | Phase 1|Phase 2 |
| NCT00335140 | Eastern Cooperative Oncology Group |
Lymphoma
|
December 2006 | Phase 2 |
| NCT01979536 | National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma, ALK-Positive|Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
|
November 8, 2013 | Phase 2 |
| NCT00002869 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia
|
April 1995 | Phase 3 |
| NCT02626338 | Arog Pharmaceuticals, Inc. |
Relapsed+Refractory Acute Myeloid Leukemia (AML)
|
February 2016 | Phase 1|Phase 2 |
| NCT01477606 | University of Ulm|Novartis Pharmaceuticals |
Acute Myeloid Leukemia
|
May 2012 | Phase 2 |
| NCT00151255 | University of Ulm |
Acute Myeloid Leukemia
|
June 2004 | Phase 3 |
| NCT04100330 | AVEO Pharmaceuticals, Inc.|Biodesix, Inc. |
Acute Myeloid Leukemia
|
January 31, 2020 | Phase 2 |
| NCT00476190 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Boston Children´s Hospital|NCIC Clinical Trials Group |
Acute Lymphoblastic Leukemia
|
April 2007 | Phase 2 |
| NCT00310128 | AIDS Malignancy Consortium|National Cancer Institute (NCI) |
AIDS-related Lymphoma|Adult Non-Hodgkin´s Lymphoma|Anaplastic Large Cell Lymphoma
|
February 2006 | Phase 2 |
| NCT00521014 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 2007 | Phase 2 |
| NCT01840566 | Memorial Sloan Kettering Cancer Center |
Non-Hodgkin´s Lymphoma
|
April 2013 | Phase 1 |
| NCT00003215 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
April 1997 | Phase 3 |
| NCT00372593 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
August 2006 | Phase 3 |
| NCT00850382 | University of Ulm |
Acute Myeloid Leukemia (AML)
|
June 2009 | Phase 1|Phase 2 |
| NCT00210314 | International Extranodal Lymphoma Study Group (IELSG) |
Lymphoma, B Cell
|
July 2003 | Phase 2 |
| NCT00101153 | University Health Network, Toronto|National Cancer Institute (NCI) |
Leukemia
|
April 2007 | Phase 1 |
| NCT03719560 | Brown University |
Diffuse Large B Cell Lymphoma
|
July 1, 2019 | Phase 2 |
| NCT00070538 | Vion Pharmaceuticals|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
June 2003 | Phase 1 |
| NCT02954653 | Pfizer |
Acute Myeloid Leukemia
|
November 28, 2016 | Phase 1 |
| NCT02059239 | Weill Medical College of Cornell University |
Hodgkin´s Lymphoma|Non-Hodgkin´s Lymphoma
|
June 4, 2014 | Phase 1|Phase 2 |
| NCT05303792 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
February 2023 | Phase 2 |
| NCT00004215 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Anemia|Leukemia|Neutropenia|Thrombocytopenia
|
August 1999 | Phase 2 |
| NCT00656617 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC |
Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)
|
April 2008 | Phase 2 |
| NCT00004905 | Loyola University|National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 2 |
| NCT00025038 | National Cancer Institute (NCI) |
Juvenile Myelomonocytic Leukemia
|
June 2001 | Phase 2 |
| NCT01870596 | National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia
|
May 2013 | Phase 2 |
| NCT04415008 | wang, jianxiang|Institute of Hematology & Blood Diseases Hospital |
CEBPA Double Mutation|Acute Myeloid Leukemia
|
June 1, 2020 | Phase 2 |
| NCT00472849 | M.D. Anderson Cancer Center|Sanofi |
Richter´s Transformation|Leukemia
|
May 2007 | Phase 1|Phase 2 |
| NCT01839240 | University of Chicago|National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
June 6, 2012 | Phase 1 |
| NCT04778410 | Gilead Sciences |
Myeloid Malignancies
|
June 28, 2021 | Phase 2 |
| NCT00085124 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
December 2003 | Phase 3 |
| NCT01729845 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia
|
December 20, 2012 | Phase 1|Phase 2 |
| NCT01187810 | South Plains Oncology Consortium |
Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Non-Hodgkin´s Lymphoma
|
August 2010 | Phase 1 |
| NCT01500161 | Texas Oncology Cancer Center |
Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Hodgkins Disease|Non-Hodgkins Lymphoma|Aplastic Anemia|Multiple Myeloma|Myelodysplastic Syndrome
|
November 2011 | Phase 2 |
| NCT00002818 | Virginia Commonwealth University|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
February 1995 | Phase 1 |
| NCT02343939 | Gilead Sciences |
Acute Myeloid Leukemia
|
July 1, 2015 | Phase 1|Phase 2 |
| NCT03962465 | University of Virginia|Pfizer|Vanderbilt University|University of Wisconsin, Madison|Virginia Commonwealth University |
B-cell Acute Lymphoblastic Leukemia
|
July 22, 2022 | Phase 1 |
| NCT02485353 | Hamid Sayar|Indiana University |
Leukemia, Myeloid, Acute
|
October 20, 2015 | Not Applicable |
| NCT00066794 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 2004 | Phase 2 |
| NCT03019640 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Indolent Adult Non-Hodgkin Lymphoma
|
October 10, 2017 | Phase 2 |
| NCT01859819 | New York Medical College |
Diffuse Large Cell Lymphoma|Burkitt´s Lymphoma|High Grade B-cell Lymphoma
|
January 2013 | Phase 2 |
| NCT00002800 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Neutropenia
|
July 1996 | Phase 2 |
| NCT01027923 | Washington University School of Medicine |
Leukemia, Myeloid, Acute
|
May 2010 | Phase 1 |
| NCT05032183 | M.D. Anderson Cancer Center |
Recurrent Adult Lymphoblastic Lymphoma|Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Lymphoblastic Lymphoma|Refractory T Acute Lymphoblastic Leukemia
|
February 17, 2022 | Phase 1|Phase 2 |
| NCT00550992 | Dutch Childhood Oncology Group|BFM Germany|CORS Monza Italy|Associazione Italiana Ematologia Oncologia Pediatrica|Australian and New Zealand Children´s Oncology Group|BFM Austria|CLCG France Belgium Portugal|COALL Germany|CPH, Czech republic|DFCI consortium USA|FRALLE France|Hong Kong|MD Anderson USA|NOPHO Scandinavian countries|PINDA, Chile|PPLLSG Poland|Seattle USA|SJCRH USA|UKCCSG United Kingdom |
Leukemia
|
January 2006 | Not Applicable |
| NCT01358253 | Ruijin Hospital |
Acute Lymphoblastic Leukemia
|
December 2010 | Phase 4 |
| NCT01246752 | University Hospital Carl Gustav Carus|German Research Foundation |
Leukemia, Myeloid, Acute
|
February 10, 2011 | Phase 3 |
| NCT00180128 | Technische Universität Dresden |
Leukemia, Promyelocytic, Acute
|
January 2000 | Phase 4 |
| NCT00199069 | Johann Wolfgang Goethe University Hospital|Deutsche Krebshilfe e.V., Bonn (Germany) |
Adult Acute Lymphocytic Leukemia
|
April 1993 | Phase 4 |
| NCT00093483 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Leukemia
|
April 2002 | Phase 1 |
| NCT02441803 | M.D. Anderson Cancer Center |
Leukemia
|
September 14, 2015 | Phase 2 |
| NCT00992446 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Diffuse Large B-Cell Lymphoma|B-Cell Non-Hodgkin Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Non-Hodgkin Lymphoma
|
September 2, 2010 | Phase 2 |
| NCT00028899 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
July 2002 | Phase 1 |
| NCT01034410 | Antisoma Research |
Acute Myeloid Leukemia
|
January 2010 | Phase 2 |
| NCT01031368 | Nohla Therapeutics, Inc.|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
December 2009 | Phase 1 |
| NCT03964090 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Central Nervous System Lymphoma|Secondary Central Nervous System Lymphoma
|
June 27, 2019 | Phase 2 |
| NCT00047268 | European Working Group of MDS in Childhood|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic+Myeloproliferative Neoplasms
|
July 1998 | Phase 3 |
| NCT00450801 | University of Miami |
Lymphoma
|
April 2004 | Phase 2 |
| NCT00945815 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
September 2010 | Phase 2 |
| NCT03900949 | Uma Borate|Ohio State University Comprehensive Cancer Center |
Acute Myeloid Leukemia
|
March 13, 2019 | Phase 1 |
| NCT03860844 | Sanofi |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia
|
August 6, 2019 | Phase 2 |
| NCT01117441 | University Hospital Schleswig-Holstein|Deutsche Krebshilfe e.V., Bonn (Germany) |
Leukemia
|
June 2010 | Phase 3 |
| NCT01621477 | St. Jude Children´s Research Hospital|Assisi Foundation |
Acute Lymphoblastic Leukemia|Acute Myelocytic Leukemia|Chronic Myelocytic Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Hodgkin or Non-Hodgkin Lymphoma|Sarcoma, Myeloid
|
August 2012 | Phase 2 |
| NCT03324243 | Arog Pharmaceuticals, Inc. |
Relapsed+Refractory FLT3-mutated AML
|
January 2018 | Phase 2 |
| NCT00004228 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 2000 | Phase 3 |
| NCT00129168 | Kanisa Pharmaceuticals |
Leukemia, Myeloid
|
August 2005 | Phase 1|Phase 2 |
| NCT00002768 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
June 1996 | Phase 2 |
| NCT01511562 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
September 2012 | Phase 2 |
| NCT03150693 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia
|
June 1, 2017 | Phase 3 |
| NCT00556127 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie |
Diffuse Large B-Cell Lymphoma|POOR PROGNOSIS
|
June 2002 | Phase 2 |
| NCT02299518 | Bhavana Bhatnagar|Karyopharm Therapeutics Inc|Ohio State University Comprehensive Cancer Center |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
May 18, 2015 | Phase 1 |
| NCT00671658 | M.D. Anderson Cancer Center |
Leukemia|Acute Lymphoblastic Leukemia
|
November 2002 | Phase 2 |
| NCT00776373 | Abramson Cancer Center of the University of Pennsylvania |
ALL|Burkitt´s Lymphoma|Lymphoblastic Leukemia|CML
|
January 2007 | Phase 1|Phase 2 |
| NCT00939653 | Therapeutic Advances in Childhood Leukemia Consortium|Genzyme, a Sanofi Company |
Relapsed Acute Myelogenous Leukemia
|
July 10, 2009 | Phase 2 |
| NCT01690507 | Chinese PLA General Hospital|Navy General Hospital, Beijing |
MDS|AML
|
November 2012 | Phase 1|Phase 2 |
| NCT05554419 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia
|
February 28, 2023 | Phase 2 |
| NCT01700946 | St. Jude Children´s Research Hospital|Cookies for Kids´ Cancer|Assisi Foundation |
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood B-Lymphoblastic Lymphoma
|
April 15, 2013 | Phase 2 |
| NCT02660762 | Sun Yat-sen University |
Leukaemia,Lymphoblastic
|
January 2016 | Phase 2 |
| NCT02724163 | University of Birmingham|Assistance Publique - Hôpitaux de Paris|Cancer Research UK|National Cancer Institute, France|Pfizer |
Acute Myeloid Leukaemia
|
April 2016 | Phase 3 |
| NCT00005603 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 2000 | Phase 3 |
| NCT00143975 | University of Ulm |
Leukemia, Myeloid, Acute
|
June 2004 | Phase 2 |
| NCT00002785 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 1996 | Phase 2 |
| NCT00137995 | Lymphoma Study Association |
Lymphoma, Large-Cell, Diffuse
|
June 2003 | Phase 3 |
| NCT00002657 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
May 1995 | Phase 2 |
| NCT00003602 | Riverside Haematology Group|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
March 1998 | Phase 3 |
| NCT00002833 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes
|
October 1994 | Phase 2 |
| NCT00003187 | Virginia Commonwealth University|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes
|
May 1995 | Phase 2|Phase 3 |
| NCT00866918 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Acute Promyelocytic Leukemia With PML-RARA|Myeloid Neoplasm
|
March 9, 2009 | Phase 3 |
| NCT01645839 | Centre Oscar Lambret |
Breast Cancer|Leptomeningeal Metastases
|
August 30, 2011 | Phase 3 |
| NCT00299182 | M.D. Anderson Cancer Center|Amgen |
Lymphoma
|
March 2006 | Phase 1|Phase 2 |
| NCT01960387 | University of Pittsburgh |
Acute Myeloid Leukemia
|
October 2013 | Phase 2 |
| NCT01145846 | Cooperative Study Group A for Hematology |
Acute Myelogenous Leukemia
|
May 2010 | Phase 3 |
| NCT00408005 | National Cancer Institute (NCI) |
T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
January 22, 2007 | Phase 3 |
| NCT03031262 | Institute of Hematology & Blood Diseases Hospital |
AML
|
February 8, 2017 | Phase 1|Phase 2 |
| NCT02905994 | Massachusetts General Hospital|Boehringer Ingelheim |
AML
|
September 2016 | Phase 1 |
| NCT04801797 | Massachusetts General Hospital|AbbVie |
Acute Myeloid Leukemia
|
May 20, 2021 | Phase 2 |
| NCT00002704 | National Cancer Institute (NCI) |
Leukemia
|
January 1996 | Phase 2 |
| NCT00003061 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
July 1997 | Phase 2 |
| NCT00266136 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany)|German Federal Ministry of Education and Research |
Acute Myeloid Leukemia
|
June 1999 | Phase 3 |
| NCT00012051 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Lymphoma
|
September 2000 | Phase 3 |
| NCT04817241 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
August 2, 2021 | Phase 1|Phase 2 |
| NCT00002798 | National Cancer Institute (NCI) |
Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Anemia With Ringed Sideroblasts|Secondary Myelodysplastic Syndromes|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
August 1996 | Phase 3 |
| NCT00002718 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
November 1995 | Phase 2 |
| NCT05456269 | Race Oncology Ltd|Astex Pharmaceuticals, Inc. |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Higher Risk Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia
|
July 2022 | Phase 1 |
| NCT00002756 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 1996 | Phase 2 |
| NCT03444649 | University Hospital Inselspital, Berne |
AML
|
September 2018 | Phase 1 |
| NCT00967512 | Eleos, Inc. |
Acute Myelogenous Leukemia
|
January 2012 | Phase 2 |
| NCT00003437 | Medical Research Council|National Cancer Institute (NCI) |
Leukemia
|
January 1997 | Phase 3 |
| NCT00472056 | M.D. Anderson Cancer Center |
Lymphoma
|
March 2005 | Phase 2 |
| NCT03263572 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Amgen|Takeda |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia|t(9;22)
|
November 29, 2017 | Phase 2 |
| NCT00513305 | Cephalon|Teva Branded Pharmaceutical Products R&D, Inc. |
Acute Myeloid Leukemia
|
October 2007 | Phase 3 |
| NCT00003423 | United Kingdom Children´s Cancer Study Group|National Cancer Institute (NCI) |
Lymphoma
|
May 1995 | Phase 3 |
| NCT03117751 | St. Jude Children´s Research Hospital|Incyte Corporation|Amgen|Servier |
Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma
|
March 29, 2017 | Phase 2|Phase 3 |
| NCT03913559 | St. Jude Children´s Research Hospital|Pfizer |
Acute Lymphoblastic Leukemia
|
May 14, 2019 | Phase 2 |
| NCT00199017 | Johann Wolfgang Goethe University Hospital |
Lymphoma, Lymphoblastic
|
April 2004 | Phase 4 |
| NCT00274807 | The Cleveland Clinic|National Cancer Institute (NCI) |
Leukemia
|
June 2001 | Phase 2 |
| NCT00669877 | M.D. Anderson Cancer Center |
Burkitt´s Lymphoma|Burkitt´S-like Lymphoma
|
August 2002 | Phase 2 |
| NCT00838240 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia|Myelodysplastic Syndromes
|
November 2008 | Phase 1|Phase 2 |
| NCT00098774 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
October 2004 | Phase 2 |
| NCT05361057 | Institute of Hematology & Blood Diseases Hospital |
Acute Myeloid Leukemia|Measurable Disease
|
May 1, 2022 | Phase 2 |
| NCT00480064 | French Innovative Leukemia Organisation |
Acute Myeloid Leukemia
|
July 1995 | Phase 3 |
| NCT01035463 | University of Nebraska|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma, ALK-Negative|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma
|
November 12, 2009 | Phase 1|Phase 2 |
| NCT04195945 | Fred Hutchinson Cancer Center|Jazz Pharmaceuticals |
Acute Myeloid Leukemia|Myeloid Neoplasm
|
March 11, 2020 | Phase 2 |
| NCT00195104 | Weill Medical College of Cornell University |
Myelodysplastic Syndrome
|
September 17, 2003 | Phase 1|Phase 2 |
| NCT01607645 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts
|
July 2012 | Phase 2 |
| NCT00541866 | Sunesis Pharmaceuticals |
Acute Myeloid Leukemia
|
October 6, 2007 | Phase 1|Phase 2 |
| NCT05554406 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic+Myeloproliferative Neoplasm|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Therapy-Related Acute Myeloid Leukemia
|
February 28, 2023 | Phase 2 |
| NCT04214249 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia
|
June 1, 2020 | Phase 2 |
| NCT00176462 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Acute Lymphocytic Leukemia
|
February 2001 | Phase 2 |
| NCT02535806 | Children´s Mercy Hospital Kansas City|Millennium Pharmaceuticals, Inc. |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
July 2015 | Phase 2 |
| NCT01670084 | Mayo Clinic |
B-cell Adult Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia
|
December 2012 | Phase 2 |
| NCT03892421 | La Raza Medical Center |
Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma
|
April 5, 2018 | Phase 1|Phase 2 |
| NCT00991744 | Nordic Society for Pediatric Hematology and Oncology|Oulu University Hospital |
Acute Lymphoblastic Leukemia
|
January 2009 | Phase 3 |
| NCT05260528 | Centre Hospitalier Universitaire de Nice|Jazz Pharmaceuticals|Acute Leukemia French Association |
Acute Myeloid Leukemia
|
April 2022 | Phase 2 |
| NCT01555268 | Roswell Park Cancer Institute|Amgen |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
October 31, 2011 | Phase 1 |
| NCT01721876 | Boehringer Ingelheim |
Leukemia, Myeloid, Acute
|
January 29, 2013 | Phase 3 |
| NCT02521493 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Down Syndrome|Myelodysplastic Syndrome|Myeloid Leukemia Associated With Down Syndrome|Myeloproliferative Neoplasm
|
November 23, 2015 | Phase 3 |
| NCT00061945 | National Cancer Institute (NCI) |
Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia
|
June 2003 | Phase 1|Phase 2 |
| NCT00689845 | University Hospital Southampton NHS Foundation Trust|National Cancer Institute (NCI) |
Lymphoma
|
June 2007 | Not Applicable |
| NCT00276601 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia
|
October 2004 | Phase 2 |
| NCT02419755 | St. Jude Children´s Research Hospital |
Mixed Lineage Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia
|
April 14, 2015 | Phase 2 |
| NCT00007852 | University of Nebraska|National Cancer Institute (NCI)|Genentech, Inc. |
Lymphoma
|
September 2000 | Phase 2 |
| NCT00290498 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
August 1, 2005 | Phase 2 |
| NCT04113616 | Kartos Therapeutics, Inc. |
Relapsed or Refractory Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
|
September 25, 2019 | Phase 1|Phase 2 |
| NCT02527174 | University of Alberta |
Leukemia, Myeloid, Acute|Leukemia, Monocytic, Acute|Leukemia, Myelomonocytic, Acute|Leukemia, Erythroblastic, Acute|Leukemia, Megakaryoblastic, Acute
|
November 2016 | Phase 1 |
| NCT00618501 | Asan Medical Center|National Cancer Institute (NCI) |
Leukemia
|
October 2005 | Phase 2 |
| NCT01876953 | City of Hope Medical Center|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
September 13, 2013 | Phase 1|Phase 2 |
| NCT00593645 | Washington University School of Medicine |
Myelodysplastic Syndromes|Acute Myeloid Leukemia
|
November 2007 | Phase 2 |
| NCT00005823 | Leukemia Research Fund|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
December 1998 | Phase 3 |
| NCT03589729 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts 10 Percent or More of Bone Marrow Nucleated Cells|High Risk Myelodysplastic Syndrome|Myeloid Sarcoma|Myeloproliferative Neoplasm|Philadelphia Chromosome Positive
|
September 19, 2018 | Phase 2 |
| NCT03926624 | Delta-Fly Pharma, Inc. |
Leukemia, Myeloid, Acute
|
November 22, 2019 | Phase 3 |
| NCT01324063 | European Organisation for Research and Treatment of Cancer - EORTC |
Leukemia
|
November 1986 | Phase 3 |
| NCT02758925 | University Hospital, Caen |
Diffuse Large B Cell Lymphoma
|
June 2016 | Phase 2 |
| NCT00003758 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia
|
December 1998 | Phase 2 |
| NCT05177731 | Chen Suning|The First Affiliated Hospital of Soochow University |
AML, Adult|Chemotherapy Effect
|
March 1, 2022 | Phase 3 |
| NCT03736616 | Swedish Medical Center|Acerta Pharma BV |
Diffuse Large B Cell Lymphoma
|
August 16, 2019 | Phase 2 |
| NCT02305563 | Bristol-Myers Squibb |
Leukemia
|
January 27, 2015 | Phase 1|Phase 2 |
| NCT00369317 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Acute Basophilic Leukemia|Childhood Acute Eosinophilic Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
March 2007 | Phase 3 |
| NCT00003934 | National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Promyelocytic Leukemia (M3)|Childhood Acute Promyelocytic Leukemia (M3)|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
|
June 1999 | Phase 3 |
| NCT00002926 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
December 1996 | Phase 3 |
| NCT02532010 | Weill Medical College of Cornell University |
Acute Myeloid Leukemia (AML)
|
June 15, 2015 | Phase 2 |
| NCT03250338 | Arog Pharmaceuticals, Inc. |
Relapsed+Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
|
June 5, 2018 | Phase 3 |
| NCT00058461 | National Cancer Institute (NCI) |
B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|L3 Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma
|
November 2003 | Phase 2 |
| NCT00019409 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Leukemia
|
October 1999 | Phase 3 |
| NCT00003783 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 1999 | Phase 2 |
| NCT03031249 | Institute of Hematology & Blood Diseases Hospital |
AML
|
February 8, 2017 | Phase 1|Phase 2 |
| NCT01853228 | Janssen Research & Development, LLC |
Acute Myeloid Leukemia
|
October 22, 2013 | Phase 1|Phase 2 |
| NCT00430118 | University Hospital Schleswig-Holstein |
Leukemia
|
July 2000 | Phase 3 |
| NCT00022490 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Leukemia
|
June 2001 | Phase 2 |
| NCT02666950 | Mayo Clinic|National Cancer Institute (NCI) |
Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic+Myeloproliferative Neoplasm|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
May 5, 2017 | Phase 2 |
| NCT00047021 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
November 2001 | Phase 2 |
| NCT01822015 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Untreated Adult Acute Myeloid Leukemia
|
March 15, 2013 | Early Phase 1 |
| NCT00064090 | Vion Pharmaceuticals|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
March 2003 | Phase 1 |
| NCT01066494 | Antisoma Research |
Acute Myeloid Leukemia
|
January 2010 | Phase 2 |
| NCT00400946 | Dana-Farber Cancer Institute|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Leukemia
|
April 2005 | Phase 3 |
| NCT00004643 | National Center for Research Resources (NCRR)|University of Michigan|Office of Rare Diseases (ORD) |
Lupus Erythematosus, Systemic
|
February 1995 | Phase 2 |
| NCT01005758 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
January 2009 | Phase 2 |
| NCT02085408 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
December 28, 2010 | Phase 3 |
| NCT00732498 | University of Arizona|National Cancer Institute (NCI) |
Lymphoma
|
May 15, 2006 | Phase 2 |
| NCT00669812 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma|Small Intestine Cancer
|
February 2008 | Phase 2 |
| NCT02883049 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|Central Nervous System Leukemia|Ph-Like Acute Lymphoblastic Leukemia|Testicular Leukemia
|
February 27, 2012 | Phase 3 |
| NCT00070174 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 2003 | Phase 2 |
| NCT01692197 | M.D. Anderson Cancer Center|Eisai Inc. |
Leukemia
|
February 1, 2013 | Phase 2 |
| NCT00039377 | National Cancer Institute (NCI) |
Adult Acute Lymphoblastic Leukemia in Remission
|
April 2002 | Phase 2 |
| NCT00651261 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Novartis Pharmaceuticals |
Leukemia
|
April 2008 | Phase 3 |
| NCT03897127 | University of Ulm|Jazz Pharmaceuticals |
Acute Myeloid Leukemia
|
September 4, 2019 | Phase 3 |
| NCT01325194 | Nordic Lymphoma Group|Mundipharma Pte Ltd.|Amgen |
Primary Disease
|
March 2011 | Phase 2 |
| NCT03349281 | Julio Barredo, MD|Takeda|University of Miami |
Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia
|
March 25, 2019 | Phase 1 |
| NCT00053131 | Roswell Park Cancer Institute |
Leukemia
|
January 1999 | Phase 2 |
| NCT05241093 | Tarapeutics Science Inc. |
Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
March 29, 2022 | Phase 2 |
| NCT04112589 | PETHEMA Foundation|Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company|Syntax for Science, S.L |
Acute Myeloid Leukemia
|
December 26, 2019 | Phase 1|Phase 2 |
| NCT00779714 | University of Wuerzburg|Hiege-Stiftung gegen Hautkrebs|medac GmbH|DCS Innovative Diagnostik Systeme |
Melanoma
|
October 2008 | Phase 3 |
| NCT03416179 | Pfizer |
Leukemia, Myeloid, Acute
|
April 20, 2018 | Phase 3 |
| NCT02432872 | Jianxiang Wang|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Acute Myeloid Leukemia
|
April 2015 | Not Applicable |
| NCT00198978 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
January 2003 | Phase 4 |
| NCT01228331 | Universitätsklinikum Hamburg-Eppendorf |
Leukemia
|
October 2010 | Phase 2|Phase 3 |
| NCT05313958 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Maternal and Child Health Hospital of Foshan|The First Affiliated Hospital of Guangzhou Medical University|Second Xiangya Hospital of Central South University|Jiangxi Province Children´s Hospital|Southern Medical University, China|The First Affiliated Hospital of Nanchang University|Guangzhou First People´s Hospital|First Affiliated Hospital of Shantou University Medical College |
Leukemia, Monocytic, Acute|Pediatric AML
|
December 1, 2021 | Phase 2|Phase 3 |
| NCT00411281 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 2006 | Phase 3 |
| NCT01515527 | M.D. Anderson Cancer Center |
Leukemia
|
February 7, 2012 | Phase 2 |
| NCT00671034 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
July 21, 2008 | Phase 3 |
| NCT00003619 | Drexel University College of Medicine|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes|Thrombocytopenia
|
February 1998 | Phase 1|Phase 2 |
| NCT00276809 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
June 2001 | Phase 2 |
| NCT00238368 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
February 2004 | Phase 2 |
| NCT00003632 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
September 1998 | Phase 2 |
| NCT01806571 | Mayo Clinic|National Cancer Institute (NCI) |
Untreated Adult Acute Myeloid Leukemia
|
March 12, 2015 | Phase 2 |
| NCT00602225 | University of Washington|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Promyelocytic Leukemia (M3)|Recurrent Adult Acute Myeloid Leukemia
|
December 2007 | Phase 1|Phase 2 |
| NCT00780104 | Abramson Cancer Center of the University of Pennsylvania |
Myeloid Leukemias|AML|Leukemia|CML
|
July 2007 | Phase 1 |
| NCT01193400 | PETHEMA Foundation|Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias |
Acute Myelogenous Leukemia
|
September 2010 | Phase 2 |
| NCT04778397 | Gilead Sciences |
Acute Myeloid Leukemia
|
July 1, 2021 | Phase 3 |
| NCT03194932 | St. Jude Children´s Research Hospital|Gateway for Cancer Research |
Acute Myeloid Leukemia
|
July 11, 2017 | Phase 1 |
| NCT00195000 | Weill Medical College of Cornell University |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
May 2003 | Phase 2 |
| NCT00734773 | Northwestern University|Pharmacyclics LLC. |
Brain and Central Nervous System Tumors|Lymphoma|Neurotoxicity
|
November 2008 | Early Phase 1 |
| NCT04326439 | Emory University |
Acute Myeloid Leukemia|AML, Childhood
|
January 24, 2020 | Phase 2 |
| NCT02756962 | Washington University School of Medicine|The Leukemia and Lymphoma Society|American Society of Hematology |
Acute Myeloid Leukemia
|
July 6, 2016 | Phase 2 |
| NCT01238211 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Core Binding Factor Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia
|
December 14, 2010 | Phase 2 |
| NCT04121819 | Peking Union Medical College Hospital |
Langerhans Cell Histiocytosis
|
October 1, 2019 | Phase 2 |
| NCT00003728 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
December 1998 | Phase 3 |
| NCT05053425 | LanZhou University |
Acute Myeloid Leukemia
|
October 20, 2021 | Not Applicable |
| NCT00004878 | Jonsson Comprehensive Cancer Center |
Graft Versus Host Disease|Leukemia
|
Phase 2 | |
| NCT00006122 | European Organisation for Research and Treatment of Cancer - EORTC |
Leukemia
|
June 2000 | Phase 2 |
| NCT05157971 | City of Hope Medical Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|Ph-Like Acute Lymphoblastic Leukemia
|
March 17, 2022 | Phase 1 |
| NCT02688140 | Technische Universität Dresden|Gruppo Italiano Malattie EMatologiche dell´Adulto|Groupe Francophone des Myelodysplasies|HOVON - Dutch Haemato-Oncology Association|Programa para el Tratamiento de Hemopatías Malignas|German Federal Ministry of Education and Research|Teva Pharmaceuticals Europe |
Acute Promyelocytic Leukemia
|
June 2016 | Phase 3 |
| NCT00025259 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma|Childhood Mixed Cellularity Classical Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Classical Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma
|
September 2002 | Phase 3 |
| NCT02881086 | Goethe University |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
August 2016 | Phase 3 |
| NCT04687761 | PETHEMA Foundation |
Leukemia, Myeloid, Acute|De Novo|Age More 60yr
|
November 4, 2020 | Phase 1|Phase 2 |
| NCT00070187 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2003 | Phase 2|Phase 3 |
| NCT02670707 | Baylor College of Medicine |
Langerhans Cell Histiocytosis
|
March 7, 2016 | Phase 3 |
| NCT02971397 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
November 2016 | Phase 2 |
| NCT00470275 | Children´s Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
May 2007 | Phase 2 |
| NCT02198482 | University of Ulm |
Acute Myeloid Leukemia (AML)|High-risk Myelodysplastic Syndrome (MDS)
|
February 2016 | Phase 2 |
| NCT01350232 | Sidney Kimmel Cancer Center at Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|Thomas Jefferson University |
Sickle Cell Anemia|Sickle Cell-hemoglobin C Disease|Sickle Cell-β0-thalassemia
|
September 2009 | Not Applicable |
| NCT00006455 | Gustave Roussy, Cancer Campus, Grand Paris |
Lymphoma
|
November 26, 1999 | Phase 3 |
| NCT00002816 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 1996 | Phase 3 |
| NCT02828358 | National Cancer Institute (NCI) |
Acute Leukemia of Ambiguous Lineage|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia
|
March 27, 2017 | Phase 2 |
| NCT04375631 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory Myelodysplastic Syndrome|Refractory Acute Leukemia of Ambiguous Lineage|Refractory Acute Undifferentiated Leukemia
|
December 3, 2020 | Phase 1 |
| NCT04024241 | Shenzhen People´s Hospital |
Acute Myelogenous Leukemia|Chemotherapy
|
September 1, 2017 | |
| NCT03724084 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
January 25, 2019 | Phase 1|Phase 2 |
| NCT02873338 | Chimerix |
Acute Myeloid Leukemia
|
August 2016 | Phase 2 |
| NCT02024308 | Changhai Hospital |
Acute Myeloid Leukemia|AML1-ETO Fusion Protein Expression
|
November 2010 | Phase 4 |
| NCT04061239 | GWT-TUD GmbH |
MDS|AML
|
August 19, 2019 | Phase 2 |
| NCT00005802 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
June 1999 | Phase 1|Phase 2 |
| NCT00002517 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes
|
March 1993 | Phase 3 |
| NCT03568994 | Baylor College of Medicine|William Marsh Rice University |
Acute Myeloid Leukemia
|
July 10, 2018 | Early Phase 1 |
| NCT00632749 | Boehringer Ingelheim |
Leukemia, Myeloid, Acute
|
May 2008 | Phase 2 |
| NCT03026842 | The First Hospital of Jilin University|The Second Affiliated Hospital of Dalian Medical University|Second Hospital of Jilin University|Jilin University |
Acute Myeloid Leukemia
|
January 2017 | Phase 4 |
| NCT00505700 | Massachusetts General Hospital|Millennium Pharmaceuticals, Inc. |
Leukemia
|
July 2003 | Phase 1 |
| NCT03570983 | Swedish Medical Center |
Multiple Myeloma
|
September 5, 2018 | Phase 2 |
| NCT00131053 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 2 |
| NCT01656031 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Leukemia
|
February 2005 | Phase 2 |
| NCT00003311 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
May 20, 1998 | Phase 2 |
| NCT02003222 | National Cancer Institute (NCI)|Canadian Cancer Trials Group |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
December 23, 2013 | Phase 3 |
| NCT02432911 | Jianxiang Wang|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Acute Myeloid Leukemia
|
April 2015 | Not Applicable |
| NCT00004086 | Garden State Cancer Center at the Center for Molecular Medicine and Immunology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
June 1997 | Phase 1 |
| NCT01130506 | National Cancer Institute (NCI) |
Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
May 17, 2010 | Phase 1 |
| NCT00005962 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
July 2000 | Phase 2 |
| NCT02784561 | Chinese PLA General Hospital|309th Hospital of Chinese People´s Liberation Army|Beijing Naval General Hospital|Space Center Hospital, Peking University |
Leukemia
|
July 2016 | Phase 4 |
| NCT00470197 | National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Malignant Neoplasm|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia
|
April 2007 | Phase 1 |
| NCT00480987 | M.D. Anderson Cancer Center|Sanofi |
Myelodysplastic Syndromes|Acute Myeloid Leukemia|Leukemia
|
July 2007 | Phase 1|Phase 2 |
| NCT02926586 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
Acute Myeloid Leukemia|Core-Binding Factor
|
January 1, 2017 | Phase 4 |
| NCT00005803 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Prolymphocytic Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Chronic Lymphocytic Leukemia|T-Cell Prolymphocytic Leukemia
|
September 1999 | Phase 1|Phase 2 |
| NCT00703820 | St. Jude Children´s Research Hospital|Genzyme, a Sanofi Company|National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
August 4, 2008 | Phase 3 |
| NCT05317403 | Medical College of Wisconsin |
Acute Myeloid Leukemia, in Relapse|Acute Myeloid Leukemia Refractory
|
July 2022 | Phase 1 |
| NCT02280525 | M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation |
Leukemia
|
March 5, 2015 | Phase 1 |
| NCT00577629 | Duke University|GlaxoSmithKline |
Lymphoma, B-Cell
|
June 18, 2005 | Phase 2 |
| NCT00002471 | Memorial Sloan Kettering Cancer Center |
Leukemia|Lymphoma
|
February 1990 | Phase 2 |
| NCT00992602 | University of Washington|National Cancer Institute (NCI) |
Central Nervous System Metastases|Leptomeningeal Metastases|Recurrent Breast Cancer|Stage IV Breast Cancer|Tumors Metastatic to Brain
|
April 2011 | Phase 2 |
| NCT00764907 | University Hospital, Motol|National Cancer Institute (NCI) |
Leukemia
|
November 2002 | Phase 3 |
| NCT00613457 | Associazione Italiana Ematologia Oncologia Pediatrica |
Leukemia
|
September 2000 | Phase 3 |
| NCT00558519 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
March 12, 2008 | Phase 2 |
| NCT00354107 | National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma
|
January 2007 | Phase 1|Phase 2 |
| NCT01174888 | Alison Walker|Novartis|Millennium Pharmaceuticals, Inc.|Ohio State University Comprehensive Cancer Center |
Acute Myeloid Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following|Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
August 2010 | Phase 1 |
| NCT02858804 | Institute of Hematology & Blood Diseases Hospital |
Mantle Cell Lymphoma
|
January 2016 | Phase 4 |
| NCT03701308 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
January 16, 2019 | Phase 2|Phase 3 |
| NCT02464657 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
July 2015 | Phase 1|Phase 2 |
| NCT00015951 | University of Maryland, Baltimore|National Cancer Institute (NCI)|University of Maryland Greenebaum Cancer Center |
Leukemia|Myelodysplastic Syndromes
|
April 2001 | Phase 2 |
| NCT03384225 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Changhai Hospital|Xiangya Hospital of Central South University|Tongji Hospital|Wuhan Union Hospital, China|Chengdu PLA General Hospital|Tang-Du Hospital|Fujian Medical University Union Hospital |
High Risk Acute Myeloid Leukemia|Allogeneic Hematopoeitic Stem Cell Transplantation
|
August 1, 2016 | Phase 3 |
| NCT03564704 | Nanfang Hospital of Southern Medical University |
Leukemia|Leukemia, Acute|Adult Lymphoblastic Lymphoma|Leukemia, Lymphoblastic|Leukemia, T Cell|Adult Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoblastic Leukemia
|
February 14, 2016 | Phase 2|Phase 3 |
| NCT00002665 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia|Neutropenia|Thrombocytopenia
|
July 1995 | Phase 2 |
| NCT02443077 | National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
|
July 6, 2016 | Phase 3 |
| NCT00407966 | National Cancer Institute (NCI) |
Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
October 2006 | Phase 2 |
| NCT00003388 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
February 1999 | Phase 2 |
| NCT00416819 | University of California, San Francisco|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Lymphoma
|
September 2003 | Not Applicable |
| NCT01768897 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia
|
January 2013 | Phase 1 |
| NCT00723658 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2008 | Phase 2 |
| NCT04547049 | First Affiliated Hospital of Zhejiang University |
Leukemia
|
September 1, 2020 | Phase 3 |
| NCT03563560 | Sumitomo Pharma Co., Ltd. |
Acute Myeloid Leukemia
|
May 15, 2018 | Phase 1 |
| NCT01101880 | University of Washington|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Refractory Anemia With Excess Blasts|Untreated Adult Acute Myeloid Leukemia|Myeloproliferative Neoplasm With 10% Blasts or Higher
|
August 2010 | Phase 2 |
| NCT00915252 | University Hospital Muenster|Celgene Corporation|Amgen |
Acute Myeloid Leukemia
|
July 2009 | Phase 2 |
| NCT04250051 | Northwestern University|Agios Pharmaceuticals|National Cancer Institute (NCI) |
Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Recurrent Myeloproliferative Neoplasm|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome
|
March 28, 2021 | Phase 1 |
| NCT05536154 | The Affiliated People´s Hospital of Ningbo University |
Lymphoma|Multiple Myeloma
|
November 1, 2022 | Not Applicable |
| NCT03914625 | National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Down Syndrome
|
June 28, 2019 | Phase 3 |
| NCT03412266 | Peking University People´s Hospital |
Myelodysplastic Syndromes
|
February 1, 2018 | Phase 2 |
| NCT01161550 | Washington University School of Medicine |
Leukemia, Myeloid, Acute
|
November 2010 | Phase 1 |
| NCT00494897 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 1996 | Phase 4 |
| NCT00720109 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
July 14, 2008 | Phase 2|Phase 3 |
| NCT03263936 | Therapeutic Advances in Childhood Leukemia Consortium |
Acute Myelogenous Leukemia
|
July 11, 2017 | Phase 1 |
| NCT00695409 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
March 18, 2008 | Phase 2 |
| NCT02635074 | Steven E. Coutre|National Cancer Institute (NCI)|Stanford University |
Recurrent Adult Acute Myeloid Leukemia
|
November 2016 | Phase 1 |
| NCT03836209 | PrECOG, LLC.|Astellas Pharma Inc |
Acute Myeloid Leukemia
|
December 6, 2019 | Phase 2 |
| NCT03021330 | Institute of Hematology & Blood Diseases Hospital |
AML
|
February 8, 2017 | Phase 3 |
| NCT02638428 | Samsung Medical Center|Ministry of Health, Republic of Korea |
Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML
|
December 2015 | Phase 2 |
| NCT00002719 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto |
Leukemia|Neutropenia
|
December 1995 | Phase 3 |
| NCT02203526 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Central Nervous System Lymphoma
|
August 14, 2014 | Phase 1 |
| NCT00908180 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma
|
July 2009 | Phase 2 |
| NCT00534469 | City of Hope Medical Center|National Cancer Institute (NCI) |
Leukemia
|
February 8, 2000 | Phase 2 |
| NCT00025636 | German Hodgkin´s Lymphoma Study Group|European Organisation for Research and Treatment of Cancer - EORTC|EBMT Solid Tumors Working Party|National Cancer Institute (NCI) |
Lymphoma
|
July 2001 | Phase 3 |
| NCT00109837 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2005 | Phase 2 |
| NCT04216524 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blastic Plasmacytoid Dendritic Cell Neoplasm
|
May 29, 2020 | Phase 2 |
| NCT01880437 | Hoffmann-La Roche |
Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
|
September 2013 | Phase 2 |
| NCT00002618 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
December 1994 | Phase 3 |
| NCT04220684 | Sumithira Vasu|Ohio State University Comprehensive Cancer Center |
Allogeneic Stem Cell Transplant Recipient|Blasts 10 Percent or More of Bone Marrow Nucleated Cells|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
June 1, 2020 | Phase 1 |
| NCT00003073 | Pacira Pharmaceuticals, Inc|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Leukemia|Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific
|
February 1997 | Phase 1 |
| NCT01656252 | PrECOG, LLC.|GlaxoSmithKline|Novartis |
Acute Myeloid Leukemia
|
July 2012 | Phase 1|Phase 2 |
| NCT05330377 | Ayman H Qasrawi|Astellas Pharma Inc|University of Kentucky |
Acute Myeloid Leukemia
|
March 2023 | Phase 1 |
| NCT05362942 | Beijing 302 Hospital |
Relapsed Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Minimal Residual Disease
|
May 1, 2022 | Phase 2 |
| NCT05601830 | Institute of Hematology & Blood Diseases Hospital |
Minimal Residual Disease
|
October 28, 2022 | Phase 1 |
| NCT02420717 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Ph-Like Acute Lymphoblastic Leukemia
|
July 15, 2015 | Phase 2 |
| NCT00002514 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Medical Research Council |
Leukemia
|
April 1993 | Phase 3 |
| NCT02532192 | M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc |
Lymphoma
|
December 2015 | Phase 1 |
| NCT01008462 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
B-Cell Prolymphocytic Leukemia|Hypodiploidy|Loss of Chromosome 17p|Plasma Cell Leukemia|Progression of Multiple Myeloma or Plasma Cell Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Small Lymphocytic Lymphoma|t(14;16)|t(4;14)|T-Cell Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia
|
March 18, 2010 | Phase 2 |
| NCT02560025 | Massachusetts General Hospital|Takeda |
Acute Myeloid Leukemia
|
December 2015 | Phase 2 |
| NCT03418038 | Mayo Clinic|National Cancer Institute (NCI) |
Clonal Cytopenia of Undetermined Significance|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Lymphoma
|
March 23, 2018 | Phase 2 |
| NCT00003729 | European Organisation for Research and Treatment of Cancer - EORTC |
Leukemia
|
December 1998 | Phase 2 |
| NCT02270788 | St. Jude Children´s Research Hospital|Arog Pharmaceuticals, Inc.|Ohio State University |
Acute Myeloid Leukemia
|
April 2, 2015 | Phase 1 |
| NCT00084838 | Dana-Farber Cancer Institute|National Cancer Institute (NCI) |
Central Nervous System Tumor, Pediatric
|
February 2003 | Phase 2 |
| NCT03318419 | Sun Yat-sen University |
Acute Lymphoblastic Leukemia
|
January 1, 2016 | Phase 2 |
| NCT05026229 | First Affiliated Hospital Xi´an Jiaotong University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Philadelphia-Positive Acute Lymphoblastic Leukemia|ALL, Adult
|
September 6, 2021 | Not Applicable |
| NCT01849276 | Northwestern University |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
March 11, 2015 | Phase 1 |
| NCT00003700 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
January 1999 | Phase 2 |
| NCT00557193 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Undifferentiated Leukemia|Childhood T Acute Lymphoblastic Leukemia
|
January 14, 2008 | Phase 3 |
| NCT00107523 | Fred Hutchinson Cancer Center |
Leukemia
|
January 2005 | Phase 1 |
| NCT02236013 | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc |
Acute Myeloid Leukemia
|
January 7, 2015 | Phase 1 |
| NCT00002481 | St. Luke´s Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
March 1990 | Phase 2 |
| NCT00516828 | NCIC Clinical Trials Group|Bayer|Canadian Cancer Trials Group |
Leukemia|Myelodysplastic Syndromes
|
July 24, 2007 | Phase 1|Phase 2 |
| NCT05510089 | The Affiliated People´s Hospital of Ningbo University |
Hematological Malignancy
|
April 1, 2022 | Phase 4 |
| NCT03016988 | Tingbo Liu|Union hospital of Fujian Medical University|Fujian Medical University |
Mantle Cell Lymphoma
|
January 2017 | Phase 2 |
| NCT01843179 | Massachusetts General Hospital |
Acute Myeloid Leukemia
|
January 2014 | Phase 2 |
| NCT02255162 | Massachusetts General Hospital|Celgene Corporation |
Acute Myeloid Leukemia (AML)|Acute Myelocytic Leukemia|Acute Myelogenous Leukemia|Acute Granulocytic Leukemia|Acute Non-Lymphocytic Leukemia
|
January 2015 | Phase 1 |
| NCT00093600 | Novartis Pharmaceuticals|Novartis |
Acute Myeloid Leukemia (AML)
|
February 2004 | Phase 1 |
| NCT05404516 | Nanfang Hospital of Southern Medical University|Guangzhou First People´s Hospital|Guangzhou Panyu Central Hospital|Institute of Hematology & Blood Diseases Hospital|Peking University People´s Hospital|Shenzhen Hospital of Southern Medical University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Core Binding Factor Acute Myeloid Leukemia
|
January 1, 2020 | Phase 2 |
| NCT04083911 | The First Affiliated Hospital of Soochow University|Second Affiliated Hospital of Soochow University|Changzhou No.2 People´s Hospital|The First People´s Hospital of Lianyungang|Jingjiang People´s Hospital|Zhangjiagang First People´s Hospital|The Second People´s Hospital of Huai´an|The Third People´s Hospital of Kunshan |
Acute Myeloid Leukemia|Induction Chemotherapy
|
April 1, 2019 | Phase 3 |
| NCT00074178 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Lymphoma
|
January 2000 | Phase 2 |
| NCT02130869 | St. Jude Children´s Research Hospital |
Neuroblastoma|Lymphoma|High-risk Tumor
|
October 10, 2014 | Phase 1 |
| NCT00003650 | UNICANCER |
Lymphoma
|
February 1997 | Phase 3 |
| NCT00121303 | Stichting Hemato-Oncologie voor Volwassenen Nederland |
Leukemia|Myelodysplastic Syndromes
|
January 2005 | Phase 3 |
| NCT02723994 | Incyte Corporation|Children´s Oncology Group |
Leukemia
|
September 30, 2016 | Phase 2 |
| NCT00801489 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|de Novo Myelodysplastic Syndrome|High Risk Myelodysplastic Syndrome|Inv(16)|Myelodysplastic Syndrome With Excess Blasts|t(16;16)|t(8;21)|Untreated Adult Acute Myeloid Leukemia
|
April 4, 2007 | Phase 2 |
| NCT01067274 | Acute Leukemia French Association|Assistance Publique - Hôpitaux de Paris |
Acute Myeloid Leukemia
|
April 2010 | Phase 3 |
| NCT05183035 | LLS PedAL Initiative, LLC|Princess Maxima Center for Pediatric Oncology (European Sponsor)|AbbVie|Roche-Genentech|EuPAL |
Acute Myeloid Leukemia
|
October 1, 2022 | Phase 3 |
| NCT00258271 | University of Rochester |
Leukemia
|
March 2005 | Phase 1 |
| NCT04217278 | University of Birmingham |
Acute Myeloid Leukaemia|Myelodysplasia
|
January 27, 2020 | Phase 3 |
| NCT00053144 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Leukemia
|
November 1999 | Phase 1 |
| NCT00103285 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
April 11, 2005 | Phase 3 |
| NCT01127009 | Case Comprehensive Cancer Center |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia
|
July 2010 | Phase 1 |
| NCT00002676 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
July 1995 | Phase 2 |
| NCT00000689 | National Institute of Allergy and Infectious Diseases (NIAID) |
Lymphoma, Non-Hodgkin|HIV Infections
|
Phase 1 | |
| NCT00055874 | Heidelberg University |
Leukemia
|
June 2002 | Phase 3 |
| NCT00126191 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital |
Burkitt Lymphoma|Non-Hodgkins Lymphoma|Atypical Burkitt Lymphoma
|
July 2005 | Phase 2 |
| NCT00003671 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 1998 | Phase 2 |
| NCT04659616 | OHSU Knight Cancer Institute|Incyte Corporation|Oregon Health and Science University |
Acute Myeloid Leukemia
|
January 14, 2021 | Phase 1 |
| NCT00003593 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
June 1999 | Phase 3 |
| NCT03765541 | University Hospital, Toulouse |
Relapsed or Refractory Acute Myeloid Leukemia
|
January 13, 2020 | Phase 3 |
| NCT01411267 | Therapeutic Advances in Childhood Leukemia Consortium|Ambit Biosciences Corporation |
Lymphoblastic Leukemia, Acute, Childhood|Myelogenous Leukemia, Acute, Childhood
|
September 1, 2011 | Phase 1 |
| NCT00002598 | Memorial Sloan Kettering Cancer Center |
Leukemia
|
June 1994 | Phase 2 |
| NCT01890746 | Novartis Pharmaceuticals|Novartis |
Acute Leukaemia
|
September 5, 2013 | Phase 2 |
| NCT04956042 | CicloMed LLC |
Refractory Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia
|
August 27, 2021 | Phase 1|Phase 2 |
| NCT00866749 | M.D. Anderson Cancer Center |
Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
September 12, 2006 | Phase 2 |
| NCT00005977 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
September 2000 | Phase 3 |
| NCT02428543 | Versailles Hospital |
Acute Myeloid Lukemia
|
July 2013 | Phase 1|Phase 2 |
| NCT03643276 | Martin Schrappe|Deutsche Krebshilfe e.V., Bonn (Germany)|University Hospital Schleswig-Holstein |
Acute Lymphoblastic Leukemia, Pediatric
|
July 15, 2018 | Phase 3 |
| NCT01653418 | Washington University School of Medicine |
Multiple Myeloma
|
September 2012 | Phase 2 |
| NCT00268229 | The Cleveland Clinic|National Cancer Institute (NCI) |
Leukemia
|
July 2003 | Phase 1 |
| NCT00058292 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
April 2000 | Phase 1 |
| NCT03808610 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia
|
April 3, 2019 | Phase 1|Phase 2 |
| NCT05020665 | Kronos Bio |
Nucleophosmin 1-mutated Acute Myeloid Leukemia
|
November 30, 2021 | Phase 3 |
| NCT00863434 | University of Washington|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia
|
February 2009 | Phase 2 |
| NCT00005596 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2000 | Phase 3 |
| NCT01769209 | Stanford University|National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia (ALL)|Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)|Recurrent Adult Acute Lymphoblastic Leukemia (ALL)|T-cell Adult Acute Lymphoblastic Leukemia (ALL)
|
March 2013 | Phase 2 |
| NCT05049473 | PETHEMA Foundation|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
Mature B-Cell Leukemia Burkitt Type|Burkitt Lymphoma (BL)|Unclassifiable Lymphoma Between DCBL and BL
|
January 2014 | Phase 2 |
| NCT00002982 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
January 1997 | Phase 2 |
| NCT02046122 | Duke University |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
July 2014 | Phase 1|Phase 2 |
| NCT02483000 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Burkitt Lymphoma|CD20-Positive Neoplastic Cells Present|Diffuse Large B-Cell Lymphoma|Indolent Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory Mature B-Cell Non-Hodgkin Lymphoma
|
February 1, 2017 | Phase 1 |
| NCT03356080 | Shanghai Tong Ren Hospital |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
July 7, 2017 | Phase 2 |
| NCT00632827 | University of California, San Francisco|Eisai Inc.|Washington University School of Medicine |
Peripheral T-Cell Lymphoma
|
July 1, 2008 | Phase 2 |
| NCT00839982 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Myelodysplastic Syndrome With Isolated Del(5q)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia
|
November 2008 | Phase 1|Phase 2 |
| NCT01424982 | M.D. Anderson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Untreated Adult Acute Lymphoblastic Leukemia
|
October 5, 2011 | Phase 2 |
| NCT03072771 | Washington University School of Medicine|Amgen |
Diffuse Large B Cell Lymphoma
|
August 1, 2017 | Phase 1 |
| NCT00422591 | M.D. Anderson Cancer Center |
Leukemia|Acute Myeloid Leukemia|AML
|
December 2006 | Phase 2 |
| NCT00337168 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
October 2006 | Phase 2 |
| NCT01356290 | Medical University of Vienna |
Medulloblastoma Recurrent|Ependymoma Recurrent|ATRT Recurrent
|
April 2014 | Phase 2 |
| NCT02545283 | Hoffmann-La Roche |
Leukemia, Myeloid, Acute
|
December 30, 2015 | Phase 3 |
| NCT00244946 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Lymphoma
|
March 2004 | Phase 1 |
| NCT02433483 | St. Jude Children´s Research Hospital|Cookies for Kids´ Cancer |
Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)
|
May 22, 2015 | Phase 2 |
| NCT02676323 | St. Jude Children´s Research Hospital |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
May 3, 2016 | Phase 1 |
| NCT02283177 | Arog Pharmaceuticals, Inc. |
Newly Diagnosed AML With FLT3 Activating Mutations
|
January 2015 | Phase 2 |
| NCT00131027 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 3 |
| NCT01249430 | National Cancer Institute (NCI) |
Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
January 20, 2011 | Phase 1 |
| NCT03118466 | Massachusetts General Hospital|Celgene |
AML
|
September 25, 2017 | Phase 2 |
| NCT01230983 | Children´s Oncology Group|National Cancer Institute (NCI) |
Cardiac Toxicity|Leukemia|Lymphoma
|
June 1996 | Phase 3 |
| NCT00480090 | University Health Network, Toronto |
Prostate Cancer
|
April 2007 | Phase 2 |
| NCT00878254 | University of Miami |
Mantle-Cell Lymphoma
|
March 25, 2009 | Phase 2 |
| NCT05192889 | St. Jude Children´s Research Hospital|AbbVie |
Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia
|
August 25, 2022 | Phase 1|Phase 2 |
| NCT00906945 | Washington University School of Medicine |
Leukemia, Myeloid, Acute
|
February 2011 | Phase 1|Phase 2 |
| NCT02249091 | GSO Global Clinical Research BV|Karyopharm Therapeutics Inc |
Acute Myeloid Leukemia (Relapsed+Refractory)
|
September 2014 | Phase 2 |
| NCT00004231 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 2 |
| NCT01802333 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
February 12, 2013 | Phase 3 |
| NCT02848183 | Samsung Medical Center |
Pediatric Acute Myeloid Leukemia
|
January 2016 | Phase 2 |
| NCT01588951 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Acute Myeloid Leukemia
|
December 2013 | Phase 2|Phase 3 |
| NCT00029523 | Pacira Pharmaceuticals, Inc |
Meningeal Neoplasms
|
April 2001 | Phase 4 |
| NCT03654716 | Dana-Farber Cancer Institute|TeamConnor Childhood Cancer Foundation|Cookies for Kids´ Cancer|Aileron Therapeutics, Inc. |
Leukemia|Brain Tumor|Solid Tumor|Lymphoma
|
November 1, 2018 | Phase 1 |
| NCT00002766 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
March 1996 | Phase 3 |
| NCT00077181 | National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia
|
January 2004 | Phase 1 |
| NCT01636609 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|High Risk Myelodysplastic Syndrome
|
November 20, 2012 | Phase 1 |
| NCT00198991 | Goethe University|Deutsche Krebshilfe e.V., Bonn (Germany)|German Federal Ministry of Education and Research |
Adult Acute Lymphocytic Leukemia
|
April 2003 | Phase 4 |
| NCT01371630 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Burkitt-Like Lymphoma With 11q Aberration|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma
|
August 26, 2011 | Phase 1|Phase 2 |
| NCT00014495 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
November 2000 | Phase 1|Phase 2 |
| NCT00529880 | Cooperative Study Group A for Hematology |
Acute Myeloid Leukemia
|
December 2004 | Phase 2 |
| NCT04898894 | St. Jude Children´s Research Hospital|Karyopharm Therapeutics Inc|AbbVie|Gateway for Cancer Research |
Acute Leukemia of Ambiguous Lineage in Relapse|Acute Myeloid Leukemia, in Relapse|Refractory Acute Leukemia of Ambiguous Lineage|Refractory Acute Myeloid Leukemia
|
November 15, 2021 | Phase 1 |
| NCT04293562 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
July 20, 2020 | Phase 3 |
| NCT02112916 | National Cancer Institute (NCI) |
Adult T Acute Lymphoblastic Leukemia|Ann Arbor Stage II Adult Lymphoblastic Lymphoma|Ann Arbor Stage II Childhood Lymphoblastic Lymphoma|Ann Arbor Stage III Adult Lymphoblastic Lymphoma|Ann Arbor Stage III Childhood Lymphoblastic Lymphoma|Ann Arbor Stage IV Adult Lymphoblastic Lymphoma|Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma|Childhood T Acute Lymphoblastic Leukemia
|
September 30, 2014 | Phase 3 |
| NCT00003631 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
August 1998 | Phase 2 |
| NCT02109627 | C. Babis Andreadis|AVEO Pharmaceuticals, Inc.|Gateway for Cancer Research|University of California, San Francisco |
Acute Myeloid Leukemia|Relapsed Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
May 1, 2015 | Phase 1 |
| NCT01039363 | Samsung Medical Center |
Acute Myeloid Leukemia
|
Phase 2 | |
| NCT00053105 | Theradex|National Cancer Institute (NCI) |
Lymphoma
|
February 2002 | Phase 1 |
| NCT02523976 | Institute of Hematology & Blood Diseases Hospital |
Acute,Leukemia, Lymphoid
|
August 1, 2015 | Phase 2 |
| NCT04914676 | University of Florida |
Acute Myeloid Leukemia
|
March 8, 2022 | Phase 2 |
| NCT01546038 | Pfizer |
Acute Myeloid Leukemia
|
June 27, 2012 | Phase 2 |
| NCT00360750 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Retinoblastoma
|
September 2005 | Not Applicable |
| NCT02779283 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia
|
January 13, 2016 | Phase 1 |
| NCT01787474 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
May 19, 2014 | Phase 1 |
| NCT02427620 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blastoid Variant Mantle Cell Lymphoma|Mantle Cell Lymphoma|Pleomorphic Variant Mantle Cell Lymphoma
|
June 3, 2015 | Phase 2 |
| NCT00002524 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
June 1993 | Phase 2 |
| NCT02835222 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Untreated Adult Acute Myeloid Leukemia
|
February 2, 2018 | Phase 2 |
| NCT00003405 | Rush University Medical Center|National Cancer Institute (NCI) |
Leukemia
|
April 1998 | Phase 2 |
| NCT00583102 | University of Iowa |
Acute Myeloid Leukemia
|
June 2001 | Phase 1|Phase 2 |
| NCT00054327 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
November 2000 | Phase 2 |
| NCT00513188 | University of Miami |
Lymphoma
|
February 2007 | Not Applicable |
| NCT03164057 | St. Jude Children´s Research Hospital |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
June 15, 2017 | Phase 2 |
| NCT02728531 | Washington University School of Medicine |
Mantle Cell Lymphoma
|
April 18, 2016 | Phase 1 |
| NCT01408160 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Adult B Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia
|
April 2013 | Phase 1 |
| NCT04509622 | AbbVie |
Acute Myeloid Leukemia (AML)
|
October 5, 2020 | Phase 3 |
| NCT02797470 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|California Institute for Regenerative Medicine (CIRM) |
HIV Infection|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Plasmablastic Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Follicular Lymphoma|Stage III Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Follicular Lymphoma|Stage IV Mantle Cell Lymphoma
|
June 23, 2016 | Phase 1|Phase 2 |
| NCT01186328 | Therapeutic Advances in Childhood Leukemia Consortium|Enzon Pharmaceuticals, Inc. |
Lymphoblastic Leukemia, Acute|Lymphoblastic Leukemia, Acute, Childhood|Leukemia, Lymphoblastic, Acute, T Cell|Leukemia, Lymphoblastic, Acute
|
August 24, 2010 | Phase 1 |
| NCT00002805 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
August 1997 | Phase 2 |
| NCT00002565 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
May 25, 1994 | Phase 3 |
| NCT00002835 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 30, 1995 | Phase 3 |
| NCT00075725 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
December 29, 2003 | Phase 3 |
| NCT04240002 | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc |
Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation + Internal Tandem Duplication (ITD)
|
February 27, 2020 | Phase 1|Phase 2 |
| NCT02419469 | M.D. Anderson Cancer Center|Jazz Pharmaceuticals |
Leukemia|Precursor-B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoma
|
November 13, 2015 | Phase 2 |
| NCT03531918 | Fred Hutchinson Cancer Center|Pfizer |
Acute Myeloid Leukemia
|
September 14, 2018 | Phase 1|Phase 2 |
| NCT03586609 | M.D. Anderson Cancer Center |
Acute Myeloid Leukemia
|
October 25, 2018 | Phase 2 |
| NCT01025154 | M.D. Anderson Cancer Center|Genzyme, a Sanofi Company |
Acute Myeloid Leukemia
|
January 2010 | Phase 2 |
| NCT02275663 | King Fahad Medical City |
Acute Myeloid Leukemia
|
December 2014 | Phase 2 |
| NCT01435343 | PETHEMA Foundation |
Acute Myeloblastic Leukemia
|
July 2012 | Phase 1|Phase 2 |
| NCT00003079 | Virginia Commonwealth University|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
September 1997 | Phase 1 |
| NCT02587871 | University of Southern California|National Cancer Institute (NCI) |
Adult Acute Myeloid Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission
|
December 12, 2018 | Phase 2 |
| NCT00003190 | National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Untreated Adult Acute Myeloid Leukemia
|
January 1998 | Phase 3 |
| NCT02937662 | Institute of Hematology & Blood Diseases Hospital |
Acute Myeloid Leukemia
|
October 2016 | Phase 2 |
| NCT01829503 | Annie Im, M.D.|University of Pittsburgh |
Acute Myeloid Leukemia
|
February 2013 | Phase 2 |
| NCT00003578 | Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
January 1993 | Phase 3 |
| NCT00017342 | Virginia Commonwealth University|National Cancer Institute (NCI) |
Leukemia
|
July 2001 | Phase 2 |
| NCT03585686 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Langerhans Cell Histiocytosis
|
June 26, 2018 | Phase 2 |
| NCT00049179 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
April 2003 | Phase 2 |
| NCT01540812 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
February 2012 | |
| NCT00908167 | St. Jude Children´s Research Hospital|National Cancer Institute (NCI)|Bayer+Onyx |
Acute Myeloid Leukemia|Infantile Leukemia (Both AML and ALL)|Myelodysplastic Syndrome|Myelodysplastic+Myeloproliferative Neoplasms|Biphenotypic Leukemia
|
September 2009 | Phase 1 |
| NCT03793478 | Daiichi Sankyo, Inc.|Innovative Therapies For Children with Cancer Consortium|Children´s Oncology Group |
Acute Myeloid Leukemia
|
August 15, 2018 | Phase 1|Phase 2 |
| NCT03491579 | University Hospital Inselspital, Berne |
AML|Relapse
|
December 2018 | Phase 1 |
| NCT01272245 | M.D. Anderson Cancer Center|Cephalon |
Leukemia
|
July 2011 | Phase 2 |
| NCT00974792 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma
|
January 2006 | Phase 2 |
| NCT00018954 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
October 1992 | Phase 2 |
| NCT00003217 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
March 1998 | Phase 1 |
| NCT00501826 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
July 11, 2007 | Phase 2 |
| NCT04688021 | Yi Luo|First Affiliated Hospital of Zhejiang University |
Leukemia|Graft-versus-host-disease
|
December 3, 2020 | Phase 2 |
| NCT02366663 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
January 2015 | Phase 3 |
| NCT02957032 | Philogen S.p.A. |
Acute Myeloid Leukemia, Relapsed, Adult
|
April 13, 2016 | Phase 1 |
| NCT00124644 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
March 2006 | Phase 1 |
| NCT00006343 | Novartis|National Cancer Institute (NCI) |
Leukemia
|
June 2000 | Phase 3 |
| NCT00180102 | Technische Universität Dresden |
Leukemia, Nonlymphocytic, Acute
|
December 2003 | Phase 4 |
| NCT00022126 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
November 2002 | Phase 2 |
| NCT03298984 | Sumitomo Pharma Oncology, Inc. |
Acute Myeloid Leukemia
|
September 25, 2017 | Phase 1 |
| NCT01830777 | Massachusetts General Hospital |
Acute Myelogenous Leukemia
|
May 2013 | Phase 1 |
| NCT02293109 | Mehrdad Abedi, MD|Amgen|University of California, Davis |
Contiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia
|
December 17, 2015 | Phase 1 |
| NCT00778375 | M.D. Anderson Cancer Center|Eisai Inc.|Genzyme, a Sanofi Company |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
October 2008 | Phase 2 |
| NCT00477412 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
April 3, 2007 | Phase 1|Phase 2 |
| NCT00130195 | Japan Adult Leukemia Study Group |
Acute Lymphoblastic Leukemia
|
September 2002 | Phase 2 |
| NCT00002532 | Hannover Medical School|National Cancer Institute (NCI) |
Leukemia
|
January 1993 | Phase 2 |
| NCT02642965 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia
|
April 25, 2016 | Phase 1|Phase 2 |
| NCT00260832 | Eisai Inc. |
Acute Myeloid Leukemia
|
November 2005 | Phase 3 |
| NCT04546399 | National Cancer Institute (NCI) |
Down Syndrome|Recurrent B Acute Lymphoblastic Leukemia
|
December 4, 2020 | Phase 2 |
| NCT00000703 | National Institute of Allergy and Infectious Diseases (NIAID) |
Lymphoma, Non-Hodgkin|HIV Infections
|
Not Applicable | |
| NCT00273884 | Xanthus Pharmaceuticals, Inc. |
Acute Myeloid Leukemia
|
August 2005 | Phase 2 |
| NCT00073957 | Beth Israel Deaconess Medical Center |
Lymphoma
|
December 2003 | Phase 2 |
| NCT00039130 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
May 2002 | Phase 2 |
| NCT01132586 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Alkylating Agent-Related Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia
|
May 2010 | Phase 1 |
| NCT01627041 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia
|
September 16, 2011 | Phase 2 |
| NCT01321346 | Therapeutic Advances in Childhood Leukemia Consortium|Novartis |
Lymphoblastic Leukemia, Acute, Childhood|Myelogenous Leukemia, Acute, Childhood|Hodgkin´s Disease|Non-Hodgkin´s Lymphoma
|
March 2011 | Phase 1 |
| NCT00165178 | Dana-Farber Cancer Institute|Boston Children´s Hospital|University of Rochester|McMaster University|San Jorge Children´s Hospital (Puerto Rico)|St. Justine´s Hospital|Maine Children´s Cancer Program|Ochsner Health System|Tulane University School of Medicine|Laval University|Columbia University |
Acute Lymphoblastic Leukemia
|
September 2000 | Phase 3 |
| NCT05372536 | Rigshospitalet, Denmark |
Supportive Care|Childhood Cancer
|
March 11, 2022 | Not Applicable |
| NCT02553460 | St. Jude Children´s Research Hospital|Gateway for Cancer Research|Baylor College of Medicine |
Acute Lymphoblastic Leukemia
|
January 29, 2016 | Phase 1|Phase 2 |
| NCT03710772 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
May 1, 2019 | Phase 2 |
| NCT01593488 | National Cancer Institute, Naples|Santobono-Pausilpon Hospital|IRCCS Azienda Ospedaliero-Universitaria di Bologna|University of Bologna |
Acute Lymphoblastic Leukemia
|
March 2012 | Phase 2 |
| NCT00866307 | Children´s Oncology Group|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia
|
February 23, 2009 | Phase 1 |
| NCT00528333 | Seagen Inc. |
Acute Myeloid Leukemia
|
September 2007 | Phase 2 |
| NCT02875093 | Polaris Group |
Acute Myeloid Leukemia
|
January 20, 2017 | Phase 1 |
| NCT00317642 | Genzyme, a Sanofi Company|Sanofi |
Acute Myelogenous Leukemia
|
August 2006 | Phase 3 |
| NCT00572065 | Weill Medical College of Cornell University |
Myelofibrosis
|
February 29, 2008 | Early Phase 1 |
| NCT02403310 | H. Lee Moffitt Cancer Center and Research Institute|Karyopharm Therapeutics Inc |
Leukemia|Acute Myeloid Leukemia|AML
|
June 18, 2015 | Phase 1 |
| NCT00006045 | Facet Biotech|National Cancer Institute (NCI) |
Leukemia
|
March 2000 | Phase 3 |
| NCT02392429 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia
|
December 8, 2015 | Phase 2 |
| NCT00006747 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Graft Versus Host Disease|Lymphoma
|
November 2000 | Phase 2 |
| NCT00882206 | Masonic Cancer Center, University of Minnesota |
Leukemia|Lymphoma
|
April 2009 | Phase 2 |
| NCT02718755 | M.D. Anderson Cancer Center|Jazz Pharmaceuticals |
Hematologic Malignancy
|
May 2018 | Phase 2 |
| NCT00540956 | Institut Paoli-Calmettes|National Cancer Institute (NCI) |
Leukemia
|
November 2006 | Not Applicable |
| NCT02038777 | Pfizer |
Acute Myeloid Leukemia
|
March 25, 2014 | Phase 1 |
| NCT00219765 | Poitiers University Hospital|Ministry of Health, France|Novartis |
Chronic Myeloid Leukemia
|
May 2001 | Phase 1|Phase 2 |
| NCT00002700 | European Organisation for Research and Treatment of Cancer - EORTC|Acute Leukemia French Association |
Leukemia|Lymphoma
|
August 1995 | Phase 3 |
| NCT00002970 | National Cancer Institute (NCI)|Children´s Cancer Group |
Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Childhood Acute Lymphoblastic Leukemia
|
June 1997 | Phase 2 |
| NCT04871607 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma
|
November 2, 2021 | Phase 2 |
| NCT00002578 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Lymphoma
|
August 1994 | Phase 2 |
| NCT01390337 | Daiichi Sankyo, Inc.|Ambit Biosciences Corporation |
Leukemia, Myeloid, Acute
|
October 2011 | Phase 1 |
| NCT02440568 | University of Illinois at Chicago|Teva Pharmaceuticals USA |
Acute Myeloid Leukemia
|
June 5, 2015 | Phase 1|Phase 2 |
| NCT00041132 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2002 | Phase 2 |
| NCT02488408 | BerGenBio ASA |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
September 2014 | Phase 1|Phase 2 |
| NCT04216771 | Fujian Medical University |
AML in Remission
|
January 2020 | Phase 2|Phase 3 |
| NCT00151242 | University of Ulm |
Acute Myeloid Leukemia
|
July 2004 | Phase 2|Phase 3 |
| NCT00199095 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
February 1997 | Phase 4 |
| NCT00016887 | German Low Grade Lymphoma Study Group|European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Studio Linfomi|Lymphoma Study Association|National Cancer Institute (NCI) |
Lymphoma
|
December 2000 | Phase 3 |
| NCT00005589 | EBMT Solid Tumors Working Party|Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 3 |
| NCT00005945 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
June 2000 | Phase 3 |
| NCT01371981 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Leukemia Cutis|Myeloid Neoplasm|Myeloid Sarcoma
|
June 20, 2011 | Phase 3 |
| NCT00004128 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto|National Cancer Institute (NCI) |
Leukemia
|
September 1999 | Phase 3 |
| NCT00968760 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Alaunos Therapeutics|Intrexon Corporation |
Lymphoma|B-cell Lymphoma
|
June 20, 2011 | Phase 1 |
| NCT00928200 | Therapeutic Advances in Childhood Leukemia Consortium |
Relapsed Acute Lymphoblastic Leukemia|Allergy to PEG e.Coli Asparaginase|Allergy to Native e.Coli Asparaginase
|
April 13, 2009 | Phase 1 |
| NCT00016016 | National Cancer Institute (NCI) |
Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia
|
February 2001 | Phase 1|Phase 2 |
| NCT04945096 | The First Affiliated Hospital of Soochow University |
Engraft Failure|Relapse|GVHD
|
July 1, 2021 | Phase 3 |
| NCT00517699 | Hoffmann-La Roche |
Lymphoma
|
September 2007 | Phase 2 |
| NCT00000658 | National Institute of Allergy and Infectious Diseases (NIAID)|Schering-Plough |
Lymphoma, Non-Hodgkin|HIV Infections
|
Phase 3 | |
| NCT00002757 | Children´s Oncology Group|National Cancer Institute (NCI)|Societe Francaise Oncologie Pediatrique|Children´s Cancer and Leukaemia Group |
Leukemia|Lymphoma
|
June 2001 | Phase 3 |
| NCT02049801 | Bruno C. Medeiros|National Cancer Institute (NCI)|Stanford University |
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia
|
December 2014 | Phase 1 |
| NCT02921061 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Mixed Phenotype Acute Leukemia|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory High Risk Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia
|
November 17, 2016 | Phase 1|Phase 2 |
| NCT00275106 | Children´s Cancer and Leukaemia Group|European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma|National Cancer Institute (NCI) |
Lymphoma
|
September 2004 | Phase 3 |
| NCT02416388 | University Hospital, Angers |
Acute Myeloid Leukemia (AML)
|
January 2015 | Phase 2|Phase 3 |
| NCT01246622 | Roswell Park Cancer Institute|Celgene Corporation |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia
|
February 7, 2011 | Phase 1 |
| NCT03012672 | University of Washington|National Cancer Institute (NCI) |
Acute Leukemia of Ambiguous Lineage|Acute Myeloid Leukemia|Myeloid Neoplasm
|
December 30, 2016 | Phase 2 |
| NCT01779843 | Massachusetts General Hospital |
Acute Myelogenous Leukemia
|
April 2013 | Phase 1 |
| NCT03591510 | Novartis Pharmaceuticals|Novartis |
FLT3-mutated Acute Myeloid Leukemia
|
March 13, 2019 | Phase 2 |
| NCT01614197 | Therapeutic Advances in Childhood Leukemia Consortium|Pfizer |
Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Lymphoma|Peripheral T-cell Lymphoma
|
March 2015 | Phase 1 |
| NCT03259516 | St. Petersburg State Pavlov Medical University |
Myelodysplastic Syndromes
|
May 25, 2017 | Phase 1|Phase 2 |
| NCT00003815 | Scotland and Newcastle Lymphoma Group|National Cancer Institute (NCI) |
Lymphoma
|
June 1994 | Phase 3 |
| NCT00022737 | National Cancer Institute (NCI) |
Childhood Acute Lymphoblastic Leukemia in Remission|Recurrent Childhood Acute Lymphoblastic Leukemia
|
October 2002 | Phase 3 |
| NCT02303821 | Amgen|Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator|Innovative Therapies For Children with Cancer Consortium |
Acute Lymphoblastic Leukemia (ALL)
|
February 16, 2015 | Phase 1 |
| NCT01555541 | C. Babis Andreadis|University of California, San Francisco|GlaxoSmithKline |
Diffuse Large Cell Lymphoma Relapsed+Refractory
|
May 25, 2012 | Phase 2 |
| NCT05476770 | Therapeutic Advances in Childhood Leukemia Consortium |
Hematologic Malignancy|AML|ALL|BPDCN|MDS|Lymphoblastic Lymphoma|Lymphoma, B-Cell|Lymphoma, T-Cell|Hodgkin Lymphoma|Mixed Phenotype Acute Leukemia|Acute Undifferentiated Leukemia
|
November 11, 2022 | Phase 1 |
| NCT01414231 | University of Leipzig |
Acute Myeloid Leukaemia
|
April 2002 | Phase 3 |
| NCT01563614 | University Hospital, Bonn|Mundipharma Research GmbH & Co KG |
Leptomeningeal Metastasis From Malignant Melanoma
|
March 2012 | Phase 1 |
| NCT01019317 | M.D. Anderson Cancer Center |
Leukemia|AML|MDS|CML
|
November 2009 | Phase 2 |
| NCT03071276 | St. Jude Children´s Research Hospital|Karyopharm Therapeutics Inc |
Acute Myeloid Leukemia (AML)
|
January 14, 2016 | Phase 2 |
| NCT01701323 | Nohla Therapeutics, Inc.|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center |
Acute Leukemia of Ambiguous Lineage|Acute Myeloid Leukemia
|
December 10, 2012 | Phase 1 |
| NCT01363128 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|Burkitt Leukemia|Burkitt Lymphoma|CD20 Positive|Childhood Acute Lymphoblastic Leukemia in Complete Remission|Lymphoblastic Lymphoma
|
July 12, 2011 | Phase 2 |
| NCT00133991 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2005 | Phase 2 |
| NCT00716066 | Fred Hutchinson Cancer Center |
Autoimmune Disease|Neurologic Autoimmune Disease|Autologous Transplant Autoimmune|Multiple Sclerosis Transplant|MS Stem Cell Transplant|Multiple Sclerosis Stem Cell Transplant|Stiff Person Syndrome|HCT for Neurologic Autoimmune Disorders|CIDP Transplant|Myasthenia Gravis Transplant|Autoimmune Nervous System Disorder|Central Nervous System Vasculitis|Cerebellar Degeneration|Chronic Inflammatory Demyelinating Polyneuropathy|Lambert Eaton Myasthenic Syndrome|Myasthenia Gravis|Neuromyelitis Optica|Opsoclonus Myoclonus Syndrome|Rasmussen Subacute Encephalitis
|
June 2008 | Phase 2 |
| NCT03020030 | Dana-Farber Cancer Institute|Servier |
Acute Lymphoblastic Leukemia, Pediatric
|
March 3, 2017 | Phase 3 |
| NCT02084563 | Hospital Israelita Albert Einstein |
Acute Myeloid Leukemia|Myeloproliferative Neoplasms|Myelodysplastic Syndromes|Myeloproliferative+Myelodysplastic Neoplasm
|
October 2012 | Phase 2 |
| NCT01969435 | Washington University School of Medicine |
Hodgkin Disease|Lymphoma, Non-Hodgkin
|
March 19, 2014 | Phase 2 |
| NCT00553943 | Lymphoma Study Association |
Lymphoma, Non-Hodgkin|Diffuse Large B-cell Lymphoma
|
July 2007 | Phase 2 |
| NCT01920737 | Memorial Sloan Kettering Cancer Center|Shire|Duke University|Weill Medical College of Cornell University|Lehigh Valley Health Network |
Leukemia
|
August 2013 | Phase 2 |
| NCT03579927 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma
|
October 3, 2019 | Phase 1|Phase 2 |
| NCT01769911 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Nasal Type Extranodal NK+T-cell Lymphoma|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I AIDS-related Lymphoma|Stage II AIDS-related Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia
|
February 2015 | Not Applicable |
| NCT00392834 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Lymphoma
|
September 2006 | Phase 2 |
| NCT01904643 | Stanford University|National Cancer Institute (NCI) |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia
|
February 2014 | Phase 1 |
| NCT00372619 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
March 2007 | Phase 1|Phase 2 |
| NCT02909972 | Aileron Therapeutics, Inc. |
Acute Myeloid Leukemia|Myelodysplastic Syndromes
|
September 2016 | Phase 1 |
| NCT00423826 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Secondary Myelofibrosis
|
January 2007 | |
| NCT01158885 | Therapeutic Advances in Childhood Leukemia Consortium|Genzyme, a Sanofi Company |
Minimal Residual Disease|Leukemia, Lymphoblastic, Acute|Leukemia, Myelogenous, Acute
|
August 2010 | Phase 2 |
| NCT00000801 | National Institute of Allergy and Infectious Diseases (NIAID) |
Lymphoma, Non-Hodgkin|HIV Infections
|
Phase 2 | |
| NCT00295841 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Leukemia
|
February 2005 | Phase 1 |
| NCT00804856 | Boehringer Ingelheim |
Leukemia, Myeloid, Acute
|
November 27, 2008 | Phase 2 |
| NCT01451515 | St. Jude Children´s Research Hospital|National University, Singapore |
Lymphoblastic Lymphoma
|
May 25, 2012 | Phase 2 |
| NCT00505921 | M.D. Anderson Cancer Center|Bayer |
Lymphoma
|
March 2003 | Phase 2 |
| NCT00080925 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
February 2004 | Phase 1 |
| NCT00488709 | PETHEMA Foundation |
Acute Myeloid Leukemia
|
May 2003 | Phase 4 |
| NCT00002771 | German CML Study Group|National Cancer Institute (NCI) |
Leukemia
|
January 1995 | Phase 3 |
| NCT00416598 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Untreated Adult Acute Myeloid Leukemia
|
November 15, 2006 | Phase 2 |
| NCT00795002 | National Cancer Institute (NCI) |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
November 2008 | Phase 2 |
| NCT04626791 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
August 3, 2021 | Phase 2 |
| NCT02121418 | University of Washington|National Cancer Institute (NCI) |
Chronic Myelomonocytic Leukemia-2|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Untreated Adult Acute Myeloid Leukemia
|
June 2014 | Not Applicable |
| NCT00057811 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Untreated Childhood Acute Lymphoblastic Leukemia
|
June 2004 | Phase 2 |
| NCT04083066 | Mingzhi Zhang|Zhengzhou University |
Primary Central Nervous System Lymphoma
|
September 5, 2019 | Phase 4 |
| NCT00027547 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
July 2001 | Phase 1|Phase 2 |
| NCT03446638 | University of Florida|Gateway for Cancer Research|Cellworks Group Inc. |
Myelodysplastic Syndromes
|
May 2019 | Not Applicable |
| NCT03792256 | Children´s Oncology Group |
Leukemia, Lymphocytic|Lymphoblastic Lymphoma|T-cell Lymphoma|T-cell Leukemia|Recurrent Disease|Acute Leukemia
|
April 11, 2019 | Phase 1 |
| NCT03850535 | Hoffmann-La Roche |
Acute Myeloid Leukemia
|
March 25, 2019 | Phase 1|Phase 2 |
| NCT01256398 | National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
|
December 14, 2010 | Phase 2 |
| NCT02583893 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia
|
October 7, 2015 | Phase 2 |
| NCT03384212 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Changhai Hospital|Xiangya Hospital of Central South University|Tongji Hospital|Wuhan Union Hospital, China|Chengdu PLA General Hospital|Tang-Du Hospital|Fujian Medical University Union Hospital |
High Risk Acute Myeloid Leukemia|Allogeneic Hematopoeitic Stem Cell Transplantation
|
August 1, 2016 | Phase 3 |
Appearance
Solid
Source
Xerocomus nigromaculatus
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
In Vitro:
H 2 O : 48 mg/mL ( 197.35 mM ; Need ultrasonic)
DMSO : 17.3 mg/mL ( 71.13 mM ; Need ultrasonic and warming)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.1115 mL | 20.5575 mL | 41.1150 mL |
| 5 mM | 0.8223 mL | 4.1115 mL | 8.2230 mL |
| 10 mM | 0.4112 mL | 2.0558 mL | 4.1115 mL |
*
Please refer to the solubility information to select the appropriate solvent.
In Vivo:
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (411.15 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution
*
All of the co-solvents are available by MCE.
References
- [1] Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6.
- [2] Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58.
- [3] Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7.
- [4] Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3.
- [5] Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79(4):685-91.
- [6] Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4(4):439-44.
- [7] Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9(3):e00756-18. Published 2018 May 8.
- [8] Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.
Synonyms
2(1H)-Pyrimidinone, 4-amino-1-β-D-arabinofuranosyl-
Cytosine, 1-β-D-arabinofuranosyl-
4-Amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
1-(Arabinofuranosyl)cytosine
Cytarabine
Aracytidine
ara-Cytosine
1-β-D-Arabinosylcytosine
1-β-Arabinofuranosylcytosine
(Arabinofuranosyl)cytosine
Cytosine β-D-arabinofuranoside
Cytosar
Cytarabinoside
U 19920
Ara-C
NSC 63878
Ac 1075
U 19920A
Cytarabin
Spongocytidine
Alexan
Cyclocide
Cytosine-1-β-arabinofuranoside
Cytosine-1-β-D-arabinofuranoside
1-(β-D-Arabinofuranosyl)cytosine
Cytosine β-D-arabinoside
Aracytin
Cytosine arabinoside
Arafcyt
Arabinocytosine
Arabinoside C
Citozar
Udicil
DepoCyte
Aracytine
Iretin
NSC 287459
Cytosar U
CHX 3311
Arabitin
Erpalfa
Tarabine PFS
Ara-cell
Cylocide
DepoCyt
Cylocide N
4-Amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
MK 8242
SCH 900242
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.